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ABSTRACT

BAYESIAN METHODS FOR OPTIMAL TREATMENT ALLOCATION
Saptarshi Chatterjee, Ph.D.
Department of Mathematical Sciences
Northern Illinois University, 2018
Sanjib Basu, Director

In chronic diseases such as cancer, physicians make multiple treatment decisions over
the course of a patient’s disease depending on his/her biological characteristics and accrued
information. Essentially, the treatment rule at each decision point is a function which takes
the patients’ biomarker information, treatment and outcome history available up to that
point as an input and returns the treatment choice as an output. In the single treatment
setting, the optimal treatment decision can be obtained by a regression model on the mean
outcome conditional on treatment and covariates, where the optimal treatment is the one
that corresponds to the most desirable mean outcome. However, due to its over dependence
on the outcome regression model, this method is heavily prone to model misspecification.
Also, given data from an observational study, the usual regression method does not control
for the confounding bias induced by the covariates affecting both treatment and outcomes.
Causal inference provides a general framework to estimate the treatment causal effect by
comparing the potential outcomes under each treatment group. However, for an individual
patient, only one potential outcome is observed limiting the direct comparison of potential
outcomes at the patient level. A handful number of methods have been proposed in the
recent precision medicine literature where they employ semi-parametric estimation methods

such as inverse probability weighting (IPWE) to predict the optimal treatment by maximizing a certain predefined value function. However, the likelihood based methods have received
little attention in this area, partly due to making model assumptions. To fill this gap, in
this dissertation, we develop two fully Bayesian semiparametric likelihood based methods to
predict the optimal treatment for a new patient based on the treatment and covariate information from an observed group of patients. In the first approach (BayesG) we extend the
idea of parametric g-formula to include a semiparametric mean function within a marginal
structural model framework. In the second approach (PSBayes), we connect the treatment
assignment mechanism to a missing data framework and build on the Penalized Spline of
Propensity Prediction (PSPP) method in the missing data literature to develop a methodology to predict and compare the potential outcomes of the new patient. The posterior
predictive potential outcome distribution is then analyzed to predict the optimal treatment.
The performance of the proposed methodologies are illustrated in five different simulation
studies covering a wide range of scenarios. Overall, the true specifications of inverse probability methods display comparable performance whereas the misspecified models perform
poorly. In the additive mean function scenarios, PSBayes outperform all other methods in
having higher accuracy in predicting true optimal treatments, whereas the inverse probability
based methods show better performance in nonlinear mean function cases. In the presence of
non effect modifiers, the BayesG approach perform better than other methods. We conclude
the dissertation by discussing the extension of our proposed methods to a dynamic treatment
setting.
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CHAPTER 1
INTRODUCTION

Clinical studies are the backbone of modern drug discovery. A clinical trial generally focuses on demonstrating the superiority or non-inferiority of a new intervention over the standard procedure (active control) or over an intervention with no active component (placebo)
at the population level. However, in many therapeutic areas such as cancer, patients show
heterogeneous response to the same treatment. Thus it is often difficult to discover a treatment which can cure all patients irrespective of their biological characteristics or medical
history. To this direction, this dissertation focuses on methodologies for tailoring treatments
to match with patients’ profiles. Specifically, we propose two Bayesian semi-parametric
methods (BayesG and PSBayes) for predicting the best treatment option for a new patient
based on an observed group of patients. In the following chapters and sections we will discuss
the important aspects related to our methods in detail.

1.1

Observational Study

Clinical research explores whether a new intervention, strategy or medical device is safe
and effective for human. Primarily, there are two types of clinical studies - randomized
clinical trials or randomized controlled trials (RCT) and observational studies. In a RCT,
volunteers are randomly assigned to specific medical product such as a drug, medical device,
medical procedures or a specific diet plan according to research design and protocols created
and managed by investigators. An important feature of this type of study is that random-
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ization is used as a tool to reduce bias among the participants. Study subjects are grouped
randomly so that the of treatments are compared on a fair ground as the randomized groups
are expected to have similar profile of biological characteristics associated with treatment
benefit.
Although RCT is considered the gold standard in clinical research for investigating safety
and efficacy of new drug(s) there are a number of factors that limit the practical usage of it.
First of all, there is an ethical concern. In a simple RCT patients are randomly allocated to
active or control group in order to remove confounding bias and to estimate the difference in
outcomes only due to the active component. However, in many scenarios it is very difficult
to conduct a blind experiment. For example, in the hypothetical randomized experiment to
investigate the causal effect of abortion in increasing the risk of breast cancer, the first step
would be to select a large set of pregnant women and then randomly divide them into two
groups based on induced abortion and the study would conclude after observing the patients
a long period of time. As one can imagine, this type of designed experiment would clearly
violate the ethical standard of clinical practice. Besides the ethical concern, a majority of
clinical trials fails to reflect the real-life scenarios specifically when the risk of adverse effects
needs to be analyzed. Traditional RCTs often do not use large population samples or do not
have adequate follow up and thus lack in gaining enough power for detecting rare adverse
effects. Besides, patients with high risk of adverse effects are usually excluded from the trial.
Observational studies, on the other hand provide an important tool in providing information on the safety and benefit of the evidence based medications. As a result, these clinical
studies are primarily used to detect and analyze the risk factors when a RCT is impossible
or unethical to conduct. However, the main challenge in observational studies lies in the fact
that the treatment allocation mechanism is not fully or partially randomized and the independent variables are not controlled by the researchers. The participants or the providers
of the study determine which intervention or therapy the participants should receive. This
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evidence based treatment assignment makes it difficult to separate out the effect of treatment on the outcome from the prognostic effect of covariates or independent variables on
the outcome. The usual regression method when applied in this setting, often produces biased estimates of the parameters related to the causal relationship between treatments and
observed outcome. The confounding bias in observational studies are well documented in
literature and statistical methods have been explored by both econometricians and statisticians to correctly estimate the causal relationship between treatment and patient’s response
(Robins, 1986; Rubin, 1974; Imbens, 2004; Heckman et al., 2014).

1.2

Personalized Medicine

Traditionally, clinical studies focused on determining treatment effect in the whole population. However, this ‘one-size-fits-all’ approach to assess treatment efficacy and safety does
not reflect patients’ heterogeneity in their biological or physiological profiles. For example,
a young patient might respond differently to a drug than an older patient do or a treatment might have different effect on a patient with genetic mutation in cytochrome enzyme
than others (Berger et al., 2014). The heterogeneity in response to the drugs are evident in
the fact that most of the conventional drug development projects are often associated with
higher attrition rate and they subsequently succumb to failures. Moreover, a drug which
works better in an early phase approved treatments for many therapeutic areas often show
less efficacy in follow-up clinical trials. As Temple and Ellenberg (2000) pointed out, this
finding can be attributed to patients’ diverse genetic profile, clinical markers (e.g. medical
history, disease severity), demographics (e.g. sex, age) and social or environmental factors
(e.g. smoking habits, education). There are two directions that one can follow to incorporate
individual heterogeneity in clinical research. The first one is to define a group of patients
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based on their baseline covariates for a predefined intervention such that the treatment effect is maximum for the group of patients. This area of research is formally called subgroup
identification which has gained lot of attention in recent years (Tian and Tibshirani, 2010;
Lipkovich et al., 2011; Berger et al., 2014; Chen et al., 2015; Loh et al., 2015; Huang et al.,
2017). The other perspective to address heterogeneity is based on synthesizing a patient’s
individual characteristics into making the optimal treatment decision to match with the patient’s profile. This area of research, referred to as Personalized Medicine is an emerging
field of medical science. We will focus on this perspective.
The primary motivation behind personalized Medicine paradigm comes from the limitation of the classical medicine approach that it cannot synthesize patient’s individual heterogeneity in treatment decision making. Personalized medicine has the ability to incorporate
all information available on the patient including genetic, physiologic, demographic or clinical information in the process to decide the most effective treatment option for his/her
profile. In the simplest form of single treatment decision, it defines a decision rule which
takes a patient’s information as an input and outputs the treatment option that the patient
should receive among the choice of available treatment options. The optimal regime corresponds to the highest gain for a patient if (s)he had followed the regime i.e. if a patient gets
a treatment according to the optimal regime it is expected that (s)he would have received
greatest clinical benefit in compared to what (s)he would have got otherwise. We will put
more light on this aspect in Chapter 2.

1.3

Research Problem

In this dissertation, we focus on developing Bayesian methodologies to predict the optimal
treatment allocation for a new patient. Our methods are based on observational study where
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we assume to have access to the treatment, response and covariate information on a group
of patients from the same population. To identify the optimal treatment for a patient we
recast our problem within potential outcome framework which will be detailed in section 3.1.
In observational study, the treatment assignments are usually driven by patients’ biological or clinical profiles. Due to the nonrandom treatment assignment mechanism, the individuals in the treated and the untreated groups may have systematic imbalance or heterogeneity
in the distribution of the covariates associated with the treatment decision. Additionally,
some of the treatment deciding factors may also affect the event of interest. Therefore, the
treatment effect on the response gets confounded with the effect of the covariates on the
response. Due to the presence of confounding bias, the standard regression analysis on the
observed values of the covariate and the treatment leads to biased estimation of the treatment effects and fail to provide the basis of treatment comparison. The main challenge in
comparing the treatment options in such settings arises from the fact that we only observe
the response corresponding to the treatment option that a patient receives, but the response
corresponding to the other treatment(s) stays unobserved. Nevertheless, a full comparison of
the treatment options requires information on the potential outcomes that a patient would
observe under each possible treatment option.
The main objective of this article is to provide basis for treatment comparison under such
setting. Specifically, we follow two different approaches to predict the potential outcomes of
the new patient under the available treatment options. In the first method (BayesG) which
is based on the notion of Bayesian g-formula, we attempt to predict the potential outcomes
by postulating a marginal structural model (MSM) which is a popular class of models in
the causal inference literature (Robins, 1998a, 1999a). There are a handful number of articles on estimation of the causal parameters using semi-parametric methods such as inverse
probability weighting method (IPWE) (Robins, 1998a, 2000). However, there are not many
likelihood based methods primarily due to the fact that parametric models require more
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assumptions. Instead of using a full parameterization, we use a likelihood based method
within Bayesian semi-parametric setting to model the potential outcomes. In the second
approach (PSBayes), we connect the treatment assignment mechanism to the missing data
framework and try to predict the missing potential outcomes using a Bayesian semiparametric imputation model. Although, the basic framework of BayesG and PSBayes are different,
they both follow the posterior predictive distribution of the new patient’s potential outcome
leading to obtain the optimal personalized treatment option.

1.4

Outline

In Chapter 2, we review literature on personalized medicine in the context of optimal
treatment selection in single stage and in multiple stage settings. In Chapter 3 we discuss
the literature on causal inference related to our research problem. To that direction, we
introduce the potential outcome framework, discuss different aspects of causal inference
in observational study. We also review literature on marginal structural model and the
parameter estimation using inverse probability weighting and parametric g-formula. Next we
connect the treatment assignment to the missing data framework and conclude this chapter
after reviewing a few imputation methods from the missing data literature. In Chapter
4 we discuss the Bayesian parametric g-formula and propose our first method (BayesG)
which is built on the extension of the Bayesian parametric g-formula. We detail the model
specifications and discuss the optimal treatment selection in the context of it. In Chapter 5,
we detail the treatment assignment mechanism and the PSPP method. Next we propose our
second method (PSBayes) which is based on the PSPP framework along with a Dependent
Dirichlet Process extension of the original specification. We also discuss the model feedback
in the context of our proposed methodology. In chapter 6, we discuss five simulation scenarios
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and compare the performance of our proposed methods with the inverse probability based
methods. Finally in Chapter 7, we conclude with a short summary and discussions of some
future research ideas.

CHAPTER 2
PERSONALIZED MEDICINE

2.1

Introduction

Personalized medicine is the tailoring of medical intervention to the patients’ needs,
characteristics as well as preferences. In traditional clinical trials to test for the drug efficacy,
large number of patients are enrolled and are randomized to the drug arm or the placebo
double-blindedly, without knowing whether the drug would work best for each individual.
The traditional path of drug development which has conventionally influenced the practice of
medicine has been based on identifying therapies which target an entire population. However,
it has become apparent that most drugs that seem extremely promising in the lab, fail
in the clinic. It is also common in medical history that patients with similar symptoms
may have different diseases, with varying causes, or the same intervention may not work
well for all patients with apparently the same disease. In other words, patients can show
significant heterogeneity in response to treatments in many different disease areas. This
heterogeneity in the patients’ response to the same therapy prompted the researchers to
make transition from the traditional ‘one-size-fits-all’ therapy to the evidence-based and datadriven personalized therapies. Personalized medicine, thus, emerges as a paradigm in medical
science that aims to improve the quality of patients’ health care by utilizing efficiently all the
available information about patient demographics, genetic or genomic features, treatment
and outcome history, ability to cope with side-effect burden etc. It also reduces the cost by
reducing over-treatment. This allows patients to be treated and monitored more precisely
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and effectively and thus providing ways that better meet their individual needs. Developing
statistical methodologies in the arena of personalized medicine has brought new challenges
that are often beyond the scope of traditional quantitative tools.
Improving clinical intervention involves finding an optimal treatment regime that would
maximize the overall benefit leading to the most favorable outcome on average from the
patient population. By treatment regime we mean the rule of assigning a treatment, available
among the possible treatments in single stage or in multiple stages to the patients based on
their observed characteristics, and thus personalizing the treatments to the patients. The
two broad perspectives of the precision medicine are to develop and find the right treatment
for a targeted subgroup that would very likely be benefited from it and to find the subgroup
of patients that share common characteristics and would likely to benefit from the particular
treatment. Also inherent is the problem of identifying biomarkers to identify such subgroups.
In developing the treatment regime the clinicians make single point or multi-stage/sequence
of decisions over the course of the disease. A single treatment decision is the simplest case
where the personalized therapy mechanism takes the patients’ characteristics as the input and
dictates the rule that assigns the best treatment among the available options to the patients.
In multi-stage therapies, decisions are made based on the accrued information of a patient
and the next treatment action is determined from the possible options and hence making
the clinical decisions evidence-based. Updating the treatment in multiple stages based on
the accrued information from the previous stage constitutes the dynamic treatment regime
(DTR). The data based on which the optimal treatment regime is estimated may come
from both clinical trials or observational studies (Murphy, 2003; Robins et al., 2008). In
observational setting, Zhang et al. (2012b) proposed a regression framework where semiparametric methods like inverse probability weighted estimator (IPWE) or doubly robust
augmented inverse probability weighted estimator (AIPWE) have been employed to estimate
the average potential outcome of the population . In contrast to the well documented inverse-
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probability weighting method, the augmented version is robust to misspecification of the
outcome regression model or the propensity score model. Zhang et al. (2012a) proposed
another direction to address the same problem by estimating the optimal treatment regime
by Bayes classifier that minimizes the weighted expected misspecification error. However,
the regression setting requires at least one model to be correctly specified which might be a
stronger assumption in some situations. In order to avoid this limitation, powerful machine
learning approaches have been proposed (Zhao et al., 2012; Moodie et al., 2012; Chakraborty
and Moodie, 2013).
Personalized clinical practice is very common and necessary for chronic diseases which
require long-term ongoing medical intervention. Examples of chronic diseases could be obesity, diabetes, alcohol and drug abuse, depression, HIV infection etc. For treating patients
with chronic diseases, clinicians individualize the treatment type and also makes sequence
of decisions following the chronic cure model (CCM) based on the patients’ case history, to
improve on the patients’ outcome. Sequences of treatments are preferred for the long-term
chronic diseases because of high inter-patient heterogeneity in response to treatment, likely
relapse, presence or emergence of co-morbidities, time-varying side effect severity and reduction of cost and burden needed otherwise for unnecessary treatment. Thus DTR offers a
path to implement the series of decisions made by the clinicians involved in the personalized
practice.

2.2

Single-stage Decision Problems

As discussed in the introduction both single and multi-stage decision making problems
arise in the personalized medicine. Decisions made by clinicians are one of the most important factors controlling the cost and quality of medical care. Medical decisions are the
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acts that convert information into action. They help determine what prevention programs
are promoted, what diagnoses are made, what tests are ordered, and what treatments are
to be assigned to the patients. In the current era of cost containment and competition, it
will be the success or failure of medical decision making that will determine the quality of
medical practice. Decision theoretic approach has long been contributing in medicine or
health care for providing a structure for gathering, organizing and integrating information
that are relevant in the decision making. Statistically oriented works in this context include
Lindley (1991), French (1986) and Parmigiani (2002). In this section we consider single-stage
decision making in the context of personalized medicine.
A single stage regime is a mapping from the available information on the patients; that is,
from the space of covariates/prognosticators, to the space of possible treatments/decisions,
the best among which is to be assigned to the patients based on the rule. Suppose we
consider a simple example where the space of decisions has two treatments A = {0, 1} and
the covariate space (say, X ) has two prognosticators X = (X1 , X2 )0 , where X could come
from clinical or pre clinical information (e.g. X1 could be age and X2 could be WBC count).
A decision rule or a single stage regime is a function d(X), which can be defined as

d(X) =




1 if X1 < 50 and X2 < 10


0 otherwise

If d(X) takes the value 1 then the treatment A = 1 is assigned while d(X) = 0 will assign
the treatment A = 0 to the patients. Thus the regime can be expressed as d(X) = I(X1 <
50 and X2 < 10). The rule may also involve a linear combination of the prognostic variables,
e.g. d(X) = I(X1 + 8 log(X2 ) < 60). Chakraborty and Moodie (2013) formulated it using a
decision theoretic framework. They conjectured that any decision is statistically evaluated
in terms of the utility and the covariate space based on which the decision would be made.
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Then for every treatment option a and covariates X ∈ X , the decision problem in terms
of utility U (X, a) can be expressed in the framework of opportunity loss function L(X, a)
which is defined as
L(X, a) = sup U (X, a) − U (X, a),

(2.1)

a

For a given X, the optimal treatment option a? , say, is obtained by minimizing the loss
L(X, a). To have the optimal treatment in the entire population, we need to further minimize L(X, a) for all X ∈ X . The most common way of specifying the utility function is
U (X, a) = Ea (Y |X), where Y is the primary outcome of the patients receiving treatment a
with covariates X.
Instead of the primary outcome Zhang et al. (2012b) considered the potential outcome
framework. Let Y a be the potential outcome for the treatment decision a i.e. if a patient
receives treatment a his/her outcome is expected to be Y a . More formally let us consider the
average potential outcome of the patients for the treatment rule d or d(X) to reflect that it
is a function of X as E(Y d ) which, under certain assumptions (please refer to section 3.1.4),
can be written as

E[Y d ] = E[E{Y d |X}] = E[E{Y |X, A = 1}d(X) + E{Y |X, A = 0}(1 − d(X))]

(2.2)

Here E(Y d ) is called the value function, also denoted by V (d) which has been expressed
in terms of the potential outcome. The assumptions of the causal inference that the covariate space contains all the information used for the treatment assignment are implicit.
Assuming the higher outcome corresponds to a better treatment decision, the optimal treatment regime is obtained by maximizing the value function V (d). Following Zhang et al.
(2012b), it can be shown that the optimal regime, say d? can be obtained by comparing
the conditional mean response given a value of the covariate for the available treatment
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options. Formally, d? = I[E(Y |X = x; A = 1) > E(Y |X = x; A = 0)]. Estimation of d?
for a given data requires the specification of Q(x, a) = E(Y |X = x; A = a). Depending
on the outcome, linear or logistic regression model can be posited for Q(x, a) for estimating
d? and V (d). However, this estimator is heavily dependent on correct specification of the
model Q(x, a) = E(Y |X = x, A = a). In fact, in the setting of single stage regime Qian
and Murphy (2011) proposed postulating a regression model and estimating the treatment
decision from the model that would maximize the overall average outcome in the population.
However, model misspecification may lead to a regime that might not contain the optimal
treatment assignment rule that would maximize V (d). To overcome sensitivity to the model
misspecification, Zhang et al. (2012b) proposed a doubly robust augmented inverse probability weighted estimator (AIPWE). This approach takes into account possible confounding
by including both propensity score model and outcome regression model in the estimator of
V (d) and because of the doubly robustness property the estimator remains consistent when
either the model for treatment assignment mechanism or the model for the distribution of
the response is correctly specified. In addition to the parametric or semi-parametric models,
powerful statistical learning methods have also been proposed in the literature for handling
data with high complexity in such settings. These are categorized into indirect methods and
direct methods. Qian and Murphy (2011), Chakraborty and Moodie (2013), Moodie et al.
(2014) and others have worked on the most popular indirect method, called Q-learning which
is a two-step regression-based approach. Since the first step of Q-learning involves fitting
a regression model (which could be both parametric or non-parametric learning approach)
of the conditional mean of outcome, there might be problem of over-fitting leading to nonoptimal ITR. Zhao et al. (2012) proposed a direct method in the framework of outcome
weighted learning (O-learning). It considers estimation of the optimal treatment regimes
from classification perspective. Instead of considering a 0-1 loss they considered a convex
surrogate loss as is done in the support vector machine (SVM) via the hinge loss. Because
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of formulating the estimation problem in the classification framework, the problem of prediction error associated with the conditional mean approximation using prediction model
relating outcome, treatment and prognostic variables can be avoided and thus it provides a
better approach to select the targeted therapy. Zhang et al. (2012a) proposed an approach
of estimating the mean outcome using regression estimator, IPWE or AIPWE to identify
the optimal treatment regimes by Bayes classifier that minimizes the expected weighted
misclassification error.
In identifying the individualized treatment rules (ITRs) decision making becomes more
accurate as more and more information becomes available on the patients. However, when all
of the information do not turn out to be relevant in this context, variable selection becomes
inevitably important to impose sparsity in the parameters, that enhance the decision making
accuracy. In the existing literature several authors have worked on variable selection using
penalized approaches in the context of discovering the ITR; for example, Qian and Murphy
(2011) developed a two-stage procedure in the framework of Q-learning to estimate the
optimal regimes using L1 penalized least squares where to justify their approach they find a
finite sample upper bound of the mean response difference between the estimated ITR and
optimal ITR. Other relevant works include penalized quadratic loss in the framework of Alearning proposed by Lu et al. (2013), variable selection methods for qualitative interactions,
presenting two variable-ranking quantities by Gunter et al. (2011). However, since these
penalization methods are primarily designed for linear regression models, they may not be
appropriate for variable selection in treatment decision making under the misspecification
of the true model. Motivated by this, Song et al. (2015) developed Penalized Outcome
Weighted Learning (POWL) that do not depend on the parametric modeling of the value
function and simultaneously estimate the optimal regime and incorporates sparsity in the
model parameters retaining the computational advantages. Apart from these, a recent article
(Jiang et al., 2017) considers survival time as the primary end-point and proposed two non-
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parametric estimators for estimating the survival function of the patients following a given
treatment regime, and derived estimation of the optimal treatment regime based on a valuebased searching algorithm.

2.3

Dynamic Treatment Regime

Dynamic treatment regime (DTR) is a sequence of decisions that needs to be made at
multiple stages through time in response to the patients’ needs and demographics that vary
over the course of the intervention. DTR is thus also known as treatment strategies (Thall
et al., 2000), adaptive treatment strategy (Murphy, 2005; Lavori and Dawson, 2008), where
the decision rules are made one per stage of intervention, that takes patients’ treatment
histories and response up to that stage as input and outputs the recommended treatment
plan for the current stage. Thus DTR constitutes series of single stage regimes which are
dependent among each other. DTR can be thought of as the key element of chronic care
model (CCM) (Chakraborty and Moodie, 2013) where treatments need to be adaptively
applied for treating the long term chronic diseases. Consider an example of DTR with two
decision points. In the first stage the intervention is induction of chemotherapy which has
two states C = {c1 , c2 }. Based on the response of the patients after stage 1, decision in
the second stage is made. Those who responded are given the second stage intervention
M = {m1 , m2 } while those who did not respond after stage 1 are given the salvation therapy
S = {s1 , s2 }. The decision in the second stage is made based on all accrued information
available from stage 1. To put it in the mathematical notations, let the baseline covariates
of a patient be denoted by X1 and hence at the baseline stage the accrued information
of the patient is h1 = X1 . For illustration let us assume that X1 has the covariates age,
WBC, gender, % CD56 expression. The decision rule in this stage is denoted by d1 (X1 )
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which outputs the treatment for the patient from the available options in C. Before going
to stage 2, all information about the patient up to stage 1 is collected and thus the accrued
information h2 will be h2 = {X1 , chemotherapy at stage 1 , X2 }, where X2 involves the
additional information after stage 1, for example, hematologic adverse event, post-induction
ECOG status, WBC, platelets, and the responder status. Thus in stage 2, 4 treatment
options are available, 2 for responder and 2 for non-responder. The decision rule in stage
2 is d2 (h2 ) which inputs h2 and outputs the treatment from available options in M for
responder and that from the available choices in S for the non-responder. Thus, the DTR,
in this case, is d = {d1 (h1 ), d2 (h2 )}. For a multi-stage decision problem with K stages
where decision needs to be made, the sequence of observations/information along with the
treatment selection rule is given by {O1 , a1 , O2 (a1 ), a2 , O3 (ā2 ), . . . , Oj (āj−1 ), . . . , OK+1 (āK )},
where aj denotes the action space at stage j, Oj (āj−1 ) denotes the observations made at
stage j corresponding to the treatment sequence āj−1 and āj = {a1 , a2 , . . . , aj } denotes the
treatment sequence up to stage j. The DTR will be given by d = {d¯1 , d¯2 , . . . , d¯K }, where d¯j
is the rule/mapping from the observation space {O1 , a1 , O2 (a1 ), a2 , O3 (ā2 ), . . . , Oj (āj−1 )} to
the action aj at stage j.
The literature review on DTR reveals that Q-learning and A-learning are the two main
approaches for estimating optimal DTR. In Q-learning regression model is assumed at each
decision point while in A-learning regression model is posited only for the contrasts among
treatments and for treatment assignment at each decision point (Zhang et al., 2013). However, the performance of both of these approaches heavily depend on the correctness of
the specified models. Thus to circumvent this limitation Zhang et al. (2013) extended the
approach of doubly robust estimation of the optimal DTR from single stage decision to
two and any finite number of decision stages. This approach not only protects the estimation from model misspecification but also gives comparable or even superior performance
compared to the Q- or A- learning methods. Zhao et al. (2015) proposed backward out-

17
come weighted learning (BOWL) and simultaneous outcome weighted learning (SOWL) for
optimizing DTR from classification perspective. Since these approaches are based on nonparametric estimator of the expected long-term outcome, misspecification of the models is
not a concern. In BOWL, the estimation of optimal DTR is reformulated as a sequence of
weighted classification problems whereas in SOWL reduces the optimal DTR estimation to
a single classification problem. As stated in Zhao et al. (2015), a convenient way to formalize the problem in finding optimal DTRs is through potential outcomes (Rubin, 1974,
1978; Robins, 1986). Relevant works include Lavori and Dawson (2004) who used multiple
imputation to estimate all potential outcomes, to compare the adaptive regimes using the
imputed outcomes, structural model to estimate the mean response that would have been
observed if the whole population followed a particular DTR (Murphy et al., 2001). The
model considered is for the marginal mean of counter-factual or potential responses in observational data for estimation of the mean response to both nonrandom and random dynamic
treatment regimes.

CHAPTER 3
CAUSAL INFERENCE

Causal inference is an important tool for identifying and analyzing the impact of a treatment or an exposure on the consequent outcome. On the other hand, the causal inference
is frequently used in missing data analysis which has a close analogy with treatment assignment mechanism in observational studies. In this chapter, we discuss the basic notions of
causal inference and missing data and draw their connections to our research problem. Part
of the discussion in causal inference is covered in Hernan and Robins (2010), and Imbens
and Rubin (2015).

3.1

Potential Outcome Framework

3.1.1

Notation

Consider the research problem we focus in this dissertation. The primary question is that
how can we choose the best treatment option for a new patient where the data comes from an
observational study? Note that, here we are addressing the problem from a physician’s point
of view. The way we are thinking is that, suppose, the physician has the ability to guess
the possible outcomes under all treatment options. That means, the physician can foresee, if
the patient had been assigned to a particular treatment option, then what his/her outcome
would be or to put it in other way what would be the patient’s potential outcome under some
pre-specified treatment option. Then it would be easier for him/her to administer the best
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option accordingly. To this direction, we first introduce the potential outcome framework
and then mathematically formulate the causal question in our research.
Although there are alternative frameworks suggested in literature (see (Dawid, 2000)) we
mainly follow the potential outcome framework as discussed in Rubin (1974, 1978). Suppose
there is a treatment variable A, a set of potential confounders X and a continuous outcome
variable Y . The underlying notion in the potential outcome framework presumes that even
though a subject (at a particular time) was exposed to a particular treatment, the same
subject (at that particular time) can be exposed to another treatment(Imbens and Rubin,
2015). For example, if a person takes aspirin to relieve from headache, the same person
could have chosen not to take aspirin or chosen to take another medication to fulfill the same
objective. This assumption, known as the positivity assumption will be formally stated in
next section. In practice, the treatment or exposure variable can be continuous or binary
or categorical. For the simplicity, we are restricting ourselves to consider only the binary
exposure; A = 0 denoting control and A = 1 denoting treatment. Let Y 0 denote the
outcome variable that would have been observed under the treatment A = 0 and Y 1 denote
the outcome variable that would have been observed under the treatment A = 1.
The variable Y 0 is referred to as the potential outcome under treatment A = 0, whereas
the variable Y 1 is termed as the potential outcome under treatment A = 1. The terminology
“potential outcome” is used because depending on the treatment the subject has received one
of the outcomes would potentially be observed. Some authors prefer to use “counterfactual
outcome” to emphasize the fact that one outcome represents the situation that has actually
occurred (factual) whereas the other outcome does not (counterfactual). For each subject,
only one of the potential outcomes (the one for which the treatment was actually received)
has been factual. Thus for the subject who has received the treatment A = a the potential
outcome Y a has been observed and hence the observed outcome Y equals the potential
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outcome Y a . This statement is formally conjectured as the consistency assumption in the
next section.

3.1.2

Observational Study

Causal inference serves as a central toolbox for many research studies stemming from
the health, social and behavioral sciences. Most of the research questions in these fields are
motivated by causal questions such as whether a new intervention works or not, whether a
new policy succeeds to reduce the crime rate in a city or if an exposure is harmful or not.
The ideal scenario to answer such research questions is to conduct a fully randomized
controlled prospective experiment in which treatment or exposures are randomly (blinded)
assigned, volunteers strictly follow the guidelines and the relevant data are collected without
error. Then assuming the data we use for the analysis comes from the population we want
to infer about, the comparison between the treated and untreated group yields a causal
interpretation.
However, such ideal experiments might be challenging to conduct in real world applications. Moreover, in many therapeutic areas conducting a randomized trial might not be
ethical or practical. These situations motivate us to rely on observational studies to reach
the goal. Performing causal inference in observational setting requires formulating the causal
question, identifying the exposure, potential confounder and the outcome variable and stating the assumptions to make the connection between the observed data and the pseudo data
which is a part of the analysis. Although some assumptions are unverifiable in observational setting, one could enrich the analysis by performing a sensitivity analysis to check the
robustness of the method to validation of those assumptions.
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Figure 3.1: Causal diagram

3.1.3

Confounding

One major goal of conducting an observational study is to estimate the treatment causal
effect on the outcome. However, in disease area such as cancer, interventions are given based
on patient characteristics. Due to the nonrandomized assignment mechanism, there is a high
possibility that the treatment groups differ in distribution of patient characteristics associated with the treatment benefit and the observed effect of the intervention is actually the
effect of a certain characteristic which makes it difficult to separate out these two effects
using standard regression method. This phenomenon is known as confounding and in observational studies it is responsible for inducing bias in the estimation if we employ standard
regression approach to estimate treatment effect.
In observational studies confounding can happen in different ways depending on the
situations. Let us focus on the problem we are considering in this dissertation. This is
an observational study where we assume to have access to the medical information of a
group of n patients. The patients’ clinical history, biological profile (say X) have influenced
doctors to prescribe a certain treatment option (say A). Apart from the patients’ covariate
and treatment information we also have records on their outcomes Y . Now the outcomes
we observe may depend on both treatment and covariate information of the subjects. The
important question is how to separate out the effect of the treatment from the effect of the
covariates on the outcome.
This situation can be illustrated by figure 3.1. In this scenario, there are two paths
through which the treatment A and the outcome Y share information: (1) The direct causal
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path A → Y and (2) the indirect path A ← X → Y between A and Y through X. Among
these two paths, if the partial path X → A can somehow be removed from path (2), the
settings would be similar to a standard regression setting where we would have two independent regressors X and A affecting the outcome Y and we could separate out the treatment
(A) effect from the effect of covariates (X) on the outcome. Under this circumstance, standard regression method would give us an unbiased estimate of the treatment causal effect,
because in the absence of confounding the association would be same as causation and the
associational measures would be sufficient to provide information on the causal measures.
But, the critical question is that under what conditions we actually can ignore the X → A
path?

3.1.4

Assumptions

When an extraneous covariate relates to both treatment and response variable, the treatment effect gets confounded by the effect of that covariate on the response. To remove the
confounding bias, researchers often use randomized experiments where the confounders are
controlled by stratification. One crucial advantage of using randomized experiment is that
it produces exchangeability in the sense that the treated and untreated individuals are exchangeable i.e. the potential outcome distribution of treated and untreated individuals are
same. Mathematically,

Ya ⊥
⊥ A for all a.
In stratified or conditional randomization one constructs stratified samples and then
implement randomization in each group which produces conditional exchangebility within
each strata. For example, if we construct strata depending on the values of the confounders X
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then randomizing patients within each strata produces same potential outcome distribution
for treated and untreated individuals. In formal notations it implies

Ya ⊥
⊥ A|X for all a.

(3.1)

In conditional randomized experiment one can easily estimate causal effect using Inverse
Probability Weighting (IPWE) (detailed in subsection 3.2.3) or parametric g-formula (detailed in subsection 3.2.4) with the help of conditional exchangeability. In observational
study we can do the same if we make the following assumptions. Without assuming these
conditions the observational data alone is insufficient to identify causal effect (Hernan and
Robins, 2010).
Consistency. This assumption states that an individual’s observed outcome is actually
the potential outcome under the treatment that individual has actually received. That
means, if a person receives treatment a then his potential outcome under treatment a would
be his observed outcome. Assuming A ∈ {0, 1} this assumption could be formally written as

Y = Y 1 A + Y 0 (1 − A).

(3.2)

No Unmeasured Confounder. This assumption is equivalent to conditional exchangeability or sequential randomization (3.1) (Robins, 1999a). Under this assumption within levels of the observed confounder X, all other predictors of outcome are assumed to be equally
distributed between the treated and the untreated groups (Hernan and Robins, 2010). Although this assumption usually holds in RCT, it can never be verified in observational studies
(analogous to Missing at Random (MAR) assumption) due to the fact that, as the investigator is not in control of the experiment, one can never be assured of whether X is the
only factor that is unequally distributed between the treated and untreated or there is/are
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some “unmeasured” confounder(s) (Hernan and Robins, 2010). Although this assumption
is not testable, a sensitivity analysis is often performed to investigate the effect of potential
unmeasured confounder on the causal parameter estimation (Robins, 1999a,b; Hernán et al.,
2000).
Positivity. Sometimes the interest might be in estimating the average causal effect over
the population. For this purpose, investigators would need some patients for each treatment
group to make the treatment effect contrasts become estimable. This condition, referred to
as “positivity” is very important for estimating the average causal effect over a population
or a subpopulation. Formally this assumption states that there is a positive probability of
receiving each of the treatment level for every combination of treatment and confounder
(Cole and Hernán, 2008). In our setup it implies

P (A = a|X = x) > 0 for all a and x

(3.3)

This assumption is also known as experimental treatment assumption because each treatment level is assumed to be received by atleast one subject (Cole and Hernán, 2008). This
assumption is violated if some treatments are not assigned to any individual in a study which
would yield biased causal estimates (Hernán et al., 2004). Robins et al. (2000) suggested the
use of structural nested model in such situation.
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3.2

Marginal Structural Model

3.2.1

Introduction

The marginal structural model (MSM) (Robins, 1999a, 2000) was introduced to estimate
the average causal effect in a population level. To take an example, consider the following
simple linear MSM for the potential outcome under treatment a

E [Y a ] = α0 + α1 a.

(3.4)

This model is different from the usual regression model in the sense that for any subject the
quantity in the left hand side is not observed for every value a and hence this model cannot
be directly fit to the observed data. Also, note that this model does not have any covariate
and is referred as the unconditional or marginal mean model. The most important advantage
of using this model is that here the parameters are directly related to the treatment causal
effect. For example, α1 = E [Y a=1 ] − E [Y a=0 ] and so estimating the parameter α1 would
lead us to obtain the average causal effect in the population.
Suppose, there is a set of covariates or confounders (say V) for which the causal effect
of treatment A on the outcome Y varies as the value of V changes and we are interested
in finding how the treatment causal effect varies for different values or levels of V. In such
cases, V is called the effect modifier. When the interest is in estimation of the marginalized
causal effect over the whole population, MSMs usually do not include covariates in the model.
However, if the interest is in estimating the causal effect for a subgroup of patients (assuming
the factor defining the subgroup is an effect modifier) we usually include effect modifier(s)
in an interaction model.
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The general form of MSM is commensurate with that of generalized linear model (GLM).
Like in GLM we can similarly express MSM as

E [Y a |V; α] = f (A, V, α).

(3.5)

where, f (·) is a known function of treatment, effect modifier and the parameter related to
the structural model. For example, if we consider Y to be binary (say, it can only take values
0 and 1), then the expression above looks like

E [Y a |V; α] = P (Y a = 1|V; α) = logit−1 {f0 (V; α0 ) + f1 (A, V; α1 )} .
where, α = (α0 , α1 )0 , α0 is for the main causal effect of treatment and α1 measure the
change of treatment causal effect as the value of effect modifier changes by one unit. These
two parameters often are of interest in causal literature.

3.2.2

Literature Review

Marginal structural models (Robins, 1998a, 2000) represent a class of causal models
which can be used to efficiently estimate the treatment causal effect in a time-fixed or timevarying setting. This model was initially proposed as an alternative to the semiparametric
g-computation algorithm estimator (Robins, 1986) and to g-estimation of set of parametric counterfactual models, known as structural nested models or SNMs (see Robins (1994,
1997, 1998b,c) for details). In the longitudinal setting with time-dependent treatments and
confounders Robins (2000) discussed two major advantages of MSMs over SNMs. First, in
case of binary outcome, MSMs can be applied on logistic models to provide semiparametric
estimate of the treatment causal effects. Second advantage lies in the application with sur-
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vival data in the absence of time dependent covariates. In these situations, time-dependent
Cox proportional hazard (PH) model is usually implemented to estimate time dependent
treatment effect. MSMs can be easily extended to the time-dependent proportional hazards
model.
MSM was originally introduced to provide a valid estimate of the causal effect of a time
varying exposure in the presence of time varying confounders (Robins, 1999a). In observational studies, the causal effect can be well estimated assuming all confounders are measured
(time dependent or time independent) (Hernán et al., 2000). The standard approach to
estimate treatment effect in such setting was to model the current outcome as a function of
past treatment and confounder history. However, Robins (1986) proved that the standard
approach to control confounding is biased in the presence of complex confounding where
the covariates predict subsequent outcome and treatment history and are themselves influenced by past treatment. This finding holds true even though we assume that we observe
every confounder which needs to be controlled (Hernán et al., 2000). Under the sequential
randomization (also known as exchangeability or no unmeasured confounders) assumption
(3.1) the parameters of MSM can be consistently estimated by performing a weighted least
square analysis. This method known as inverse probability weighting (Robins, 1998a,b, 2000;
Robins et al., 2000) will be detailed in the next subsection.

3.2.3

Inverse Probability Weighting

Let us recall the confounding scenario as illustrated in figure 3.1. The set of characteristics
X of a patient influence the physicians to assign a treatment A. Apart from the covariate X
and the assigned treatment a, the outcome Y is also observed. Suppose, we are interested in
estimating the effect of A on Y in this situation. The parameters in the marginal structural
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model (3.4) directly correspond to the treatment causal effects. However, fitting this model
would require to know the potential outcome under each treatment option for each patient.
Clearly, it is not possible since for each patient one of the potential outcomes is counter
factual.
A crude analysis in this situation will be to posit the following associational model on
the outcome based on treatment

E[Y |A] = α00 + α10 A

(3.6)

The associational treatment effect is measured by the estimate of α10 . The parameters
of the associational model (3.6) will be different from that of the causal model (3.4) unless
the treatment is not associated with any predictor of the outcome i.e. unless we can ignore
the causal path X → A in figure 3.1. If the treatment is unconfounded, the estimate of α10
would be unbiased for the causal treatment parameter α1 .
In observational study the assumption of unconfounded treatment is not valid and therefore the associational parameter would not be same as the causal parameter. Under the assumption of ’no unmeasured confounders’ (3.1) Robins (1998a,b, 2000); Robins et al. (2000)
developed a weighted analysis to consistently estimate the causal parameter where the weight
of ith subject with treatment option ai has the following form

Wi =

1
.
P [Ai = ai |Xi ]

The denominator of the weight Wi is the probability that a patient receives his/her own
observed treatment, also known as the propensity score. For randomized experiments the
propensity score is known to the experimenter, whereas in observational studies the propen-
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sity score is generally not known and can be estimated by postulating a logistic regression
model of the treatment (Ai ) on the observed set of confounders (Xi )

logit{P (Ai = 1|Xi , γ)} = X0i γ
One can obtain the estimated weight (Ŵi ) in terms of γ̂ by fitting this model to the
observed data. Thus ith patient with Ai = 0 would be assigned the weight of Ŵi = 1 +
exp(X0i γ̂), whereas if ith patient receives Ai = 1 the corresponding weight would be Ŵi =
1 + exp(−X0i γ̂). Once, the estimated weights are obtained we can fit the association model
(3.6) on the weighted data. This method is known as inverse probability (IP) weighting and
the weighted estimators are referred to as IPWE estimators (Robins et al., 2000).
IP weighting creates a pseudo population consisting of Wi copy of ith patient. Under
the assumption that we have measured all confounders, the pseudo population replicates the
situation of an experimental study where the treatments are not confounded. Therefore the
causal parameters can be consistently estimated by the associational model (3.6) parameter
estimates based on the pseudo population data.
IPWE estimation is sensitive to the weights assigned to each patient. If Wi has extreme
values (large or small), IPWE leads to inefficient estimation. Robins et al. (2000) recommended to use stabilized weight SWi =

P (Ai =ai )
P (Ai =ai |Xi )

in these situations. The mean of stabilized

weights is expected to be 1 as the size of the pseudo population equals the study population
(Hernan and Robins, 2010).
IPWE estimators was first introduced as a class of semi-parametric estimators for the
causal parameters of marginal structural models in time-varying setting (Robins, 1998a,b,
2000; Robins et al., 2000). These articles compared IPWE with previously proposed parametric structural nested models and discussed their advantages and disadvantages. Robins
et al. (2000) explained the idea in a simplified point-treatment setting, multilevel treatment
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and unsaturated MSMs for binary outcome. Hernán et al. (2000) introduced IPWE estimation for survival outcome and showed the advantage of MSM along with IPWE estimation
in the presence of time-dependent risk factor for survival and in the situation when the past
treatment history predicts subsequent risk factor level. Although the two stage estimation
of IPWE method is well justified in frequentist semi-parametric theory, there are a very few
articles concerning IPWE method or propensity score adjustment in the Bayesian paradigm.
The primary reason lies in the fact that Bayesian inference is generally based on the full
model specification, while IPWE is not derived from likelihood based model. Despite this
fact, there have been a few attempts to introduce Bayesian version of IPWE in the causal
inference literature (Hoshino, 2008; Kaplan and Chen, 2012; Saarela et al., 2015). Among
them Saarela et al. (2015) proposed a Bayesian formulation of IPWE without specifying
the MSM in the Bayesian framework. However, as Robins et al. (2015) pointed out, their
approach may not be claimed as fully Bayesian as a propensity score model is formulated
in the design stage and the model parameters being independent of outcome model parameters, a Bayesian inference cannot be a function of the propensity score. The limitation of
casting IPWE to Bayesian framework motivates us to consider an alternative standardization method, known as parametric g-formula as an alternative to IP weighting which will be
discussed in next subsection.

3.2.4

Parametric g-formula

Parametric g-formula (Robins, 1986) provides an alternative approach to IP weighting
method that can be used to estimate the causal parameter in MSM. Similar to IP weighting
method, g-formula can also appropriately adjust for measured confounders in longitudinal
setting in presence of time dependent confounders and treatments (Young et al., 2011). This
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method was first introduced by Robins (1986) to investigate the causal effect of arsenic on
heart disease in an occupationally exposed cohort. Afterwards, it has been applied few times
in causal inference literature (Robins et al., 2004; Young et al., 2011; Keil et al., 2014).
The motivation behind this method comes from the fact that the average potential outcome over the whole population can be thought of a weighted average of the stratum specific
average of the potential outcomes. More formally, if Y a is the potential outcome under treatment a then the average potential outcome for the whole population E[Y a ] can be expressed
as the weighted average

a

Z

E[Y ] =

E[Y a |X]f (X)dX

x

where the weight comes from the distribution of the confounders. Moreover, if we assume
that we measure all the confounders of the treatment effect (’no unmeasured confounders’ or
exchangeability (3.1)) and the observed outcome is actually the potential outcome under the
treatment a patient receives (consistency (3.2)) the average potential outcome for treatment
a can be expressed as
Z

a

E[Y ] =
ZX
=

E[Y a |X]f (X)dX
E[Y a |X, A = a]f (X)dX

[exchangeability]

E[Y |X, A = a]f (X)dX.

[consistency]

(3.7)

X

Z
=
X

In ideal settings such as when X is categorical or low dimensional, one could estimate
the conditional mean of the response E[Y |X, A = a] nonparametrically by dividing the data
of the treatment group a into some strata based on different combinations of values of X
and taking average outcome for each strata. However, the nonparametric estimation is not
possible even if we have moderately high number of confounders with different levels and
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is completely out of the question if we have continuous confounders. In these situations,
we have no other option but modeling the conditional response. The parametric g-formula
extends the idea of g-formula in a parametric setting where the conditional components
are characterized by some parametric models. Specifically, we can reformulate the average
potential outcome as

a

Z

E[Y |θ] =

E[Y |X, A = a, θ 1 ]f (X, θ 2 )dX
X

where θ 1 is the set of parameters representing the conditional distribution of Y |X, A = a,
θ 2 is the set of parameters in the marginal distribution of X and θ = (θ 01 , θ 02 )0 .
Under this formulation, the estimation of causal effect is again a weighted analysis similar to IP weighting method. Here the only difference is the weight, which comes from the
marginal distribution f (X) of the confounder, can be directly incorporated in the associational model for the outcome surface and thus it is a one step procedure. The equivalence
between parametric g-formula and IP weighting is proved in literature (please refer to Technical Point 2.3 in (Hernan and Robins, 2010) for details). However, estimators based on
parametric g-formula are more efficient (smaller variance) than the estimators based on IP
weighting possibly due to its dependence on the parametric framework (Young et al., 2011).
Another advantage of parametric g-formula is that, unlike IP weighting, parametric gformula is based on likelihood based method. Motivated by this fact Keil et al. (2015)
introduced a Bayesian framework for parametric g-formula in time-fixed data and discussed
its advantage over IP weighting in the context of Bayesian formulation of counterfactual
distributions. Bayesian IPWE methods (Saarela et al., 2015) require the prior information
from structural outcome models. However, in certain applications, informative prior often
comes in the form of conditional, non-structural model parameters (Keil et al., 2015) and so
this prior information cannot be fully utilized in Bayesian IPWE setting.
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3.3

The Causal Question

Depending on the area of concern, the causal question might be at individual level or at
population level. The difference between ‘individual’ and ‘population’ requires different tools
to answer the questions. For example, when a new drug comes to the market, the healthcare
policy regulators are concerned with whether prescribing this drug to a population in certain
therapeutic area would increase the frequency of desired outcome keeping the frequency of
adverse events within a certain boundary. On the other hand, a physician is concerned with
whether recommending this drug to his/her patient would alleviate the cause of the patient’s
visit. To answer the first scenario one has to estimate the average causal effect of the new
drug in the population. In second scenario the interest is in the individual patient level.
Typically, in this situation, analysis and inference are done with the observed set of patients
under the assumption that the set of patients are sampled from the same population where
the new patient is coming from. Then, the result of the analysis is used to predict whether
the new patient would respond to the drug or not.
Recently, there have been a few attempts to introduce tailored therapeutics where the
authors are interested in finding the best treatment option not for an individual but for
a population or a group of patients. In this spirit, Zhang et al. (2012b,a) used potential
outcome framework to define the “best” treatment regime (in single stage decision problems
the regime is defined by a classification rule) so that if the “best” regime is applied to the
whole population that would yield the highest reward (best outcome, assuming larger value
is better) on average. In formal notations, if a patient with baseline information X receives
treatment according to the regime d then the potential outcome corresponding to the regime
d would be given by
Y d = Y 1 d(X) + Y 0 (1 − d(X)).
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The optimal regime for the whole population is defined by

d? = argmax E[Y d ],
d

where, E[Y d ] = EX [EY d |X [Y d |X]] is the average value of the regime over the whole population. Keil et al. (2015) considered a Bayesian framework of the parametric g-formula
and applied it in the context of obtaining the posterior predictive distribution of potential outcome for a group of patients under some pre-defined regime both in time-fixed and
time-varying setting.
In contrast to these methods for a group of patients in a population, we focus in the
comparison of different treatment options with respect to a physician or a patient’s point of
view. The inherent research question lies on the notion of individual causal effect which is
defined based on the contrast of potential outcomes of that specific individual. However, as
we have discussed earlier, for each patient we only observe the factual outcome corresponding
to the treatment (s)he has received and so for estimating individual causal effect for a new
patient we must have to rely on potential predictive distribution. Motivated by this line
of thinking, our goal is to predict the mean potential outcome for each treatment option.
Then assuming higher value of outcome is better, the optimal treatment option would be
the one corresponding to the highest average outcome value. In the next two chapters, we
will introduce the mathematical formulation of the proposed methods.

3.4

Connection to Missing Data

There is a strong connection between the treatment assignment and the missing data
mechanism. Note that, in our setting for a single patient, we do not observe the outcome
simultaneously for both treatment options. Rather we only have information on the observed
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outcome which corresponds to a treatment that the patient has been administered. Under
the consistency assumption (3.2), the observed outcome is the potential outcome under
the given treatment. It implies that we only observe one potential outcome for each patient
while the other potential outcome corresponding to the treatment that (s)he has not received
remains unobserved which raises the analogy between treatment assignment and missing data
mechanism. In this section we briefly review some of the missing data methods that we will
use in the later chapters.

3.4.1

Missing Data Mechanism

Let DF be the full dataset containing all relevant data; observed or unobserved. The
unobserved values of a dataset can be characterized by the missing data pattern. Adhering
to the notations commonly used in the missing data literature, let the variable R denote the
response indicator such that R = 1 corresponds to an observed value and R = 0 implies the
corresponding value is missing. R denotes the response indicator matrix. In this dissertation,
we assume that the missingness can only occur at the outcome variables. Accordingly, the
dimension of R only corresponds to the potential outcomes in DF . Given the response
indicator, we can partition the full dataset DF into two parts - one part DoF where the
data is fully observed and the other part Dm
F with missing observations. The missing data
mechanism i.e. the relationship between missingness and the variables plays a crucial role
in estimating marginal or conditional mean of the variable containing missing values. Rubin
(1976) considered R as a stochastic variable and described the missing data mechanism by
the conditional distribution of R given DF , f (R|DF , θ) where θ represents the unknown
relevant parameters. The missing data mechanism can be classified into three categories:
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(i) Missing completely at random (MCAR): When missingness does not depend on any
data, observed or unobserved

f (R|DF , θ) = f (R|θ) for all DF , θ

(ii) Missing at random (MAR): When missingness only depends on the observed part of
the data DoF
f (R|DF , θ) = f (R|DoF , θ) for all DoF , θ
(iii) Missing not at random (NMAR): When missingness depends on both the observed and
unobserved part of the data

f (R|DF , θ) = f (R|DoF , Dm
F , θ) for all θ

The MCAR mechanism is a special case of the MAR mechanism. In practice, the MAR
mechanism is often employed by collecting data on covariates related to nonrespondents.
In our setting, if we perceive the full data DF with n observations and p predictors

0
1
, Yn×1
, An×1 , Xn×p then the response indicator matrix R would be comas DF = Yn×1
pletely specified by the observed treatment indicator A as it can be assumed as R =
(An×1 , 1n×1 − An×1 ). The observed data would be DoF = D = (Yn×1 , An×1 , Xn×p ) where
Yn×1 is the vector of observed outcomes and the missing data would consist of the vector
miss
of missing counterfactual outcomes i.e. Dm
F = Yn×1 . Also, note that, the response indi1
0
cators for Yn×1
and for Yn×1
sum to 1n×1 implying that two potential outcomes cannot

be simultaneously observed which essentially reiterates the fundamental problem of causal
inference.
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3.4.2

Imputation Methods

Many methods have been proposed in the missing data literature for imputing the missing
observations where the end goal is to reduce bias in estimation of the mean response due to
missingness. In an oversimplified approach complete case analysis and weighted complete
case analysis (Cochran, 1968; Little, 1986; Horvitz and Thompson, 1952) ignore subjects
with missing values and the loss of information from these patients result in less efficient
estimator of the mean of the concerned parameter involving missingness. A better alternative
could be to assume the following linear regression model for the missing observations

Y = X0 β + 

where, X, say has p predictors X1 , X2 , . . . , Xp and β are the corresponding regression coefficients.  is the error term with  ∼ N (0, σ 2 ). Suppose, there are r observed cases and
n − r missing cases. Then for imputing the ith missing observation for i = (r + 1), . . . , n,
one can estimate the regression coefficients β by MLE based on the complete cases and then
predict the missing observation Ŷi by Ŷi = X0i β̂. After predicting the missing observations

P
Pn
r
Y
+
Ŷ
.
the marginal mean of the response µ can be estimated by Ŷ = n−1
i
i
i=1
i=r+1
Gelman et al. (1995) explored Bayesian version of this methodology where they imputed
the missing response values from the posterior distribution multiple times and combined the
mean values from each imputed set to estimate the marginal mean. Assuming the correct
model specification, these parametric methods are effective in correctly estimating µ under
MAR mechanism (Zhang and Little, 2009). However, they are prone to produce biased
estimates under model misspecification.
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There are several ways to achieve robustness in the model specification. In one such
attempt (linear in weight prediction (LWP) (Scharfstein et al., 1999; Bang and Robins,
2005)) the inverse of the estimated propensity score is included as a linear weight term in
the imputation model as follows,

(Y |X, β, γ) ∼ N (g(X, β) + αŵ(X, γ), σ 2 )

where, ŵ(X, γ) = 1/P̂ (R = 1|X, γ̂) is the inverse of the estimated propensity score to re

sponse for the observed cases. For the cases where Y is missing, ŵ(X, γ) = 1/ 1 − P̂ (R = 1|X, γ̂) .
Propensity weighting is a very popular tool in the missing data literature. However, one potential limitation of this approach is that it may cause large variance in estimation as it
assigns huge weights to the respondents with very small propensity scores which may result
in out-of-range estimates for the means (Little and Rubin, 2014).
Robustness can also be achieved by employing semiparametric and nonparametric methods which relaxes the model assumption by capturing nonlinear relationship between variables through a flexible mean function. To this direction, for a single covariate X, one can
build an imputation model based on penalized spline framework (Eilers and Marx, 1996;
Berry et al., 2002) Y |X, β ∼ N (s(X), σ 2 ) with a truncated polynomial basis function

s(X) =

q
X
j=0

j

βj X +

K
X

βqk (X − τk )q+

(3.8)

k=1

where, 1, X, . . . , X q , (X − τ1 )q+ , . . . , (X − τK )q+ is the truncated power basis of degree of q, K
is the total number of knots, τ1 < τ2 < · · · < τK are pre-selected fixed knots. The penalized


least square estimator β̂ = β̂0 , . . . , β̂q , β̂q1 , . . . , β̂qK can be obtained by mininimizing the
penalized error sum of squares
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n
X
i=1

(
Yi −

q
X
j=0

βj Xij

+

K
X
k=1

)2
βqk (Xi −

τk )q+

+λ

K
X

ζ (βqk )

k=1

where, λ is a smoothing parameter which can be estimated by and ζ(·) is a suitable nonnegative penalty function. Although, this imputation model is driven by parameter specifications, it gains flexibility due to the inclusion of a non-linear mean function and imitates a
nonparametric model when the number of knot points is very large.

3.4.3

Penalized Spline of Propensity Prediction (PSPP)

The previous approach is very effective for imputing missing observations for a single
covariate. In presence of more than one covariate, one might want to extend this method by
employing a multivariate spline in the response model. However, due to the curse of high
dimensionality, these methods fail to perform effectively and often produce biased estimates.
Motivated by this concern, Little and An (2004) proposed an alternative method where instead of including all predictors through a multivariate spline model, they included the spline
on a function of a subset of covariates which are more sensitive to model misspecification.
Specifically, they estimated the propensity score for each subject and a suitable function of
the propensity score is used in the response model in order to adjust for confounding.
Following Zhang and Little (2009) here we describe the method in more detail. Suppose,
we observe a group of n subjects whose response vector is denoted by Y where we use the
same response indicator R introduced before such that R = 1 corresponds to the respondents
and R = 0 implies that the response observation is missing. Let the covariates are denoted
by X = (X1 , X2 , . . . , Xp )0 which are assumed to be fully observed for all patients. We also
assume that the missing data pattern follows missing at random (MAR) mechanism. Based
on the observed data, the propensity to response can be defined as P (R = 1|X1 , . . . , Xp ).
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A spline function on the logit of the propensity score (say, P ? ) is then included in the
imputation model non-parametrically using
(X2 , . . . , Xp |P ? ) ∼ Np−1 ((s2 (P ? ) , . . . , sp (P ? )) , Σ)
(3.9)


(Y |P ? , X2 , . . . , Xp ; β) ∼ N s (P ? ) + g P ? , X2? , . . . , Xp? ; β , σ 2
where, sj (P ? ) = E (Xj |P ? ) , j = 2(1)p denotes a spline function for the regression of Xj on
P ? with the form (3.8); Xj? = Xj − sj (P ? ) represents the remainder part of Xj not explained
by the propensity score; s (P ? ) is the spline of Y on P ? of the same form (3.8) and g(·) is a
parametric function characterized by the unknown parameter β.
The specification of the PSPP model (3.9) requires the covariates X2? , . . . , Xp? to be centered by regressing X2 , . . . , Xp on splines of P ? . Zhang and Little (2009) simplified this
formulation by including the original covariates X2 , . . . , Xp in the parametric function g
without centering as follows:


(Y |P ? , X2 , . . . , Xp ; β) ∼ N s (P ? ) + g (P ? , X2 , . . . , Xp ; β) , σ 2 .

(3.10)

Imputing a missing observation by a single value does not reflect the uncertainty involved
in the prediction of the unknown missing value. Uncertainty quantification of an estimator is
a very critical part of statistical inference which would not be possible here, as the resulting
variance of the estimated parameters will be under biased towards 0. To address this concern,
An and Little (2008) proposed three approaches to estimation of the standard error calculated
from the singly imputed data for incorporating added variability due to imputation, and
the properties of the resulting confidence intervals. One of these methods is developed
under Bayesian paradigm which involves multiple draws from the joint posterior-predictive
distribution of the missing values under the PSPP model and the standard error is computed
using multiple-imputation combining methodology proposed in Rubin (2004). We will adopt
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a similar approach in chapter 5 to impute the missing potential outcomes for the new patient
and then the optimal treatment would be deduced by comparing the potential outcome
distributions under both treatment options.

CHAPTER 4
BAYESIAN G-FORMULA BASED OPTIMAL TREATMENT
ALLOCATION

4.1

Introduction

In this dissertation, we are focusing on estimating the optimal treatment decision of a
future patient where the data in consideration comes from an observational study. The
primary questions we are interested here are that how we can define the “best” treatment
and how to choose the “best” option for a new patient. The terminology “best” is somewhat
subjective and we define it with the help of potential outcome framework. Let X̃ and Ỹ
represent the confounders (biological profile) and the outcome of the new patient. Note
that, we are looking at this research problem from a physician’s point of view and hence
assume that, for the new patient we know the value of X̃, while Ỹ is unobserved. We define
the “best” treatment for the new patient as a function of the observed confounder in the
following way


a? (X̃) = argmax U a, X̃
a

where, U (·) is the utility or reward function defined as in a decision theoretic framework and
represents the reward of assigning treatment a to a patient with confounder value X̃. We
assume higher utility or reward corresponds to the better treatment. For this dissertation,
we are restricting ourselves to a point treatment study with two treatment options (e.g.
A = 0: Control and A = 1: Treatment). We assume that observed patients were assigned
one of the two treatment options and the best treatment for the new patient will be one of
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these two options. A natural choice of the utility function under the average loss function is




a
U a, X̃ = E Ỹ |X̃ under which the best treatment decision can be expressed as


?

a



a (X̃) = argmax E Ỹ |X̃ .
a

where, Ỹ a is the potential outcome of new patient if (s)he is administered treatment a.
We explore Bayesian methodologies to predict the potential outcome of the new patient
which would be observed under a given treatment option. To this end, we obtain the posterior
predictive distribution of the potential outcome which eventually leads us to the optimal
decision. In the BayesG method, we consider a semi parametric Bayesian approach to
estimate the treatment causal parameters using a marginal structural model based on the
observed data which facilitates the optimal personalized treatment selection for the new
patient. As the data we consider comes from observational study, we adjust for possible
confounders for improved estimation of causal parameters. The parameters in the marginal
structural model are estimated by g-formula within a semi-parametric Bayesian setting.
Our BayesG method gains precision due to its likelihood based construction. Unlike the
common frequentist semi-parametric methods we do not need to specify two separate models
for treatment specification and outcome regression based on treatment and confounders.
Saarela et al. (2015) proposed a Bayesian approach for IPWE. However, Robins et al.(2015),
on a discussion of Saarela et al. (2015) questioned the conceptual validity of propensity score
approach in Bayesian paradigm. We circumvented this issue in our approach by standardizing
the parameters through a prior on the confounders. The second advantage in our method is
that it can be argued to be robust to model misspecification in predicting treatment choice
probabilities.
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4.2

4.2.1

Method

Framework

We consider the potential framework (Rubin, 1978) as discussed in earlier chapters. Suppose, we observe the data D = (Y, A, X) where Y, A and X denote the outcome, treatment
and confounder information of n patients in a time fixed setting i.e. the information are
collected only once for each patient. In general, the treatment can be continuous (e.g. dose
measurement) or categorical (multiple treatment levels). For the sake of simplicity we are
restricting ourselves to dichotomous treatment with two options (0 or 1). For now, we only
focus on continuous outcome Y where it is assumed that larger values of outcome is better.
Furthermore, we assume that the three assumptions discussed in section 3.1.4 hold true
for the observed dataset. That means, by consistency assumption, the observed outcome
for a patient is actually the potential outcome under the observed treatment level. Mathematically, Y a = Y for subjects with treatment A = a. By exchangeability or ignorability
assumption, we measure all characteristics (confounders) that are involved in treatment decision making so that given a confounder set x, the treatment assignment can be assumed
to be randomized. Formally, p(Y a |A = a, X = x) = p(Y a |X = x). Positivity assumption
implies that for a given level of confounders, there are some patients in each treatment group
i.e. P (A = a|X = x) > 0. Usually, exchangeability assumption does not hold in observational setting as the study design is not in control of the investigator. So one needs to verify
it by performing sensitivity analysis.
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4.2.2

Marginal Structural Model

The marginal structural model (MSM) provides a formal way to estimate the treatment
causal effect on the marginal mean of potential outcomes given a subset of confounders, as
discussed in section 3.2. Specifically, let the set of confounders X = (V, W) includes two
subsets V and W. V includes only those confounders for which the treatment causal effect
varies with the change of V in the sense of effect modification and thus are included in the
modeling part of MSM. W is the other part of the confounder set which is not part of effect
modification but we still need to adjust it for confounding. Following (3.5), the MSM can
take a general form for continuous response. In our case, we assume a linear form as the
following
0

E [Y a |V; α] = D? α

(4.1)

where D? is a vector consisting of effect modifier and treatment variables which needs to be
specified based on which causal parameters we are interested in estimating. For example, if
we are interested in estimating the causal effect in the presence of an effect modifier, we can
consider an interaction model in the MSM with D? = (1, A, V, AV )0 and α = (α0 , α1 , α2 , α12 )0
where α1 is the parameter corresponding to the marginal causal effect of the treatment and
α12 reflects how the treatment causal effect changes w.r.t a unit change in the effect modifier.
Several semi-parametric (such as inverse probability weighting) methods have been proposed
for estimating the causal parameters (Robins, 1999a,b, 2000; Robins et al., 2000; Saarela
et al., 2015). Instead, we consider the g-formula [(Robins, 1986)] in the Bayesian setting
utilizing its likelihood based formulation. Although, the standard g-formula requires full
parameterization of the outcome model, we consider a semi-parametric approach which we
will elaborate in the next subsection. We also note that while most of recent research on
Marginal Structural models focused in the estimation perspective, out interest here is on
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the prediction perspective of predicting the potential outcome for a patient for which the
confounder information is observed.

4.2.3

Bayesian Parametric g-formula

We are interested in the marginal distribution of the potential outcome under treatment
a which we denote by Y a . This prompts us to consider the parametric g-formula (Robins,
1986) for obtaining the likelihood of the potential outcomes. Under the assumptions of (3.1),
(3.2) and (3.3) a general form of the parametric g-formula estimate for the potential outcome
distribution for treatment a is given by

a

Z

p(Y |θ) =

p(Y |A, X, θ 1 )p(X, θ 2 )dX

(4.2)

X

where, the parameter vector θ includes θ 1 and θ 2 corresponding to the parameters in the
conditional model p(Y |A, X) and the parameters in the probability of confounders p(X).
As Keil et al. (2015) pointed out, there are some advantages of recasting the parametric
g-formula within the Bayesian paradigm. The frequentist version of parametric g-formula is
dependent on the parametric specification of two unknown quantities - (1) the conditional
mean model of the outcome based on the confounder and the treatment and (2) the marginal
probability of the confounder. In complex scenarios such as when X is high dimensional or
in presence of high correlation among the observations, the parameters of these two models
might be poorly estimated. Under these scenarios, the usual method is to apply a more
parsimonious model or to employ a semi or fully Bayesian framework to improve stability
of the parameter estimates by incorporating prior information. The Bayesian version of gformula, on the other hand, gets benefited from the variance reduction properties of Bayesian
framework under the setup of parametric g-formula.
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Keil et al. (2015) provided a Bayesian parametric formulation of the potential outcome
distribution by calculating the posterior predictive distribution of the potential outcome.
With the assumptions of conditional exchangeability, consistency and independent parameters, they showed that the potential outcome distribution can be expressed as a function of
observed data D, target population distribution of confounders X, the given exposure a under Bayesian Parametric g-formula setup. Mathematically, the potential outcome predictive
distribution can be expressed as
Z

a

p(Ỹ |D) =
Zθ

p(Ỹ a , θ|D)dθ
(4.3)
a

p(Ỹ |θ, D)p(θ|D)dθ

=
θ

where, Ỹ denotes the outcome in the context of Bayesian predictive setting, p(θ|D) is the
posterior distribution of the parameters θ representing the relationship within the observed
data and p(Ỹ a |θ, D) is the predictive distribution of the potential outcome. Under the
assumption of independent parameters θ 1 and θ 2 for the outcome and confounder model,
(4.2) along with (4.3) implies
Z Z

a

p(Ỹ |D) =

p(Ỹ |A, X̃, θ 1 , D)p(X̃|θ 2 , D)p(θ|D)dX̃dθ
θ

X̃

where, X̃ denotes the confounder in the context of Bayesian predictive setting, p(X̃|θ 2 ) is the
predictive distribution of the confounder X and p(Ỹ |A, X̃, θ 1 ) is the predictive distribution
corresponding to the observed outcome. The samples drawn from posterior distribution of θ
would contain all information of the observed dataset D so that p(X̃|θ 2 , D) = p(X̃|θ 2 ) and
p(Ỹ |A, X̃, θ 1 , D) = p(Ỹ |A, X̃, θ 1 ) making

a

Z Z

p(Ỹ |D) =

p(Ỹ |A, X̃, θ 1 )p(X̃|θ 2 )p(θ|D)dX̃dθ
θ

X̃

(4.4)
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Note that, while the parametric g-formula (4.2) directly depends on the parameters θ,
the Bayesian version of g-formula marginalizes over the parameters θ and thus is more robust
to model misspecification (Keil et al., 2015).
The Bayesian parametric g-formula does not give us insight on a particular patient’s
treatment choice as it marginalizes over the possible values of the confounder X, making it
suitable for estimating the causal effect at the population level, but not at the individual
level. Instead of directly applying Bayesian parametric g-formula, we formulate the potential
outcome distribution at the individual level as
Z

a

p(Ỹ |X̃, D) =
Zθ
=

p(Ỹ a , θ|X̃, D)dθ
p(Ỹ a |θ, X̃, D)p(θ|X̃, D)dθ

(4.5)

θ

Z
=

p(Ỹ a |θ, X̃)p(θ|D)dθ

θ

where X̃ and Ỹ a denote the new patient’s observed confounder and the potential outcome
under treatment a. The likelihood p(Ỹ a |θ, X̃) conditions on the new patient’s confounder
information and hence through this formulation, we can incorporate the future patient’s
confounder information into the treatment decision making.
Both formulations (4.4) and (4.5) follow the Bayesian setting. In the first one, the
common approach is to assume a parametric model for the outcome surface conditional


distribution p Ỹ |X̃, θ and put prior on the parameters involved. While this approach may
produce more stable estimates, due to its over reliance on parametric assumptions, it may
not work well in variety of scenarios. Instead of fully parameterizing the outcome surface
model and placing informative or non-informative priors on the parameters, we propose to
consider a semi-parametric Bayesian model for the outcome distribution within marginal
structural model setup where we directly synthesize the confounders information through a

49
flexible Gaussian Process (GP) prior (Bernardo et al., 1998) on the confounders distribution.
The details of the likelihood model is given in the next subsection.

4.2.4

Bayesian Inference

Likelihood Model. We build a likelihood model within the framework of marginal
structural model as in Roy et al. (2016). We assume the outcome distribution to be parametric where the confounders contribute to a part of the mean function of the outcome model
through GP prior such that the mean function is commensurate with that of the MSM (4.1).
For concreteness, we assume the following expression for the outcome likelihood model:

p (Y a |φ(X); α, σy ) = N Y ; g(A, V; α) + φ(X), σy2



(4.6)

where, φ(·) : Rp → R is the function of p-variate confounders, α are the parameters in the
MSM (4.1) and σy is the standard deviation of the outcome model. The likelihood model is
formulated under the condition that, the mean potential outcome conditioned on a specific
value of the effect modifier E [Y a |V] is same for (4.1) and (4.6). g(A, V; α) is a function
of the treatment and the effect modifier which works as a buffer in order to maintain the
connection between the likelihood model and the MSM.
Gaussian Process Prior. Following the works of Xu et al. (2016); Roy et al. (2016)
we assume the functions φ(X) are independent observations from a Gaussian Process (GP)
prior (Bernardo et al., 1998). For a finite (say, k) number of vectors each with p components
X = (X1 , X2 , . . . , Xk )0 the distribution of φ(X) = (φ(X1 ), φ(X2 ), . . . , φ(Xk ))0 is given by a
k dimensional multivariate normal distribution as follows

φ(X) ∼ Nk (µ(X), C(X))
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where, µ(X) = (µ(X1 ), µ(X2 ), . . . , µ(Xk ))0 is the k×1 mean vector and C(X) = C(X1 , X2 , . . . , Xk )
is the k × k covariance matrix. In short, we denote this by φ(X) ∼ GP(µ(X), C(X)). The
mean and covariance functions of a GP can assume a very general form.
In our case, we specify GP for the observed dataset with n observations. Let, X =
(X1 , . . . , Xn )0 where, Xi = (Xi1 , . . . , Xip )0 . We include the regression function of the non
effect modifiers W = {Wij , i = 1(1)n, j = 1(1)p} in the prior mean of φ(X) to model the
dependence of φ(X) as a function of W. Mathematically, we assume,

(φ(X)|β, η, ρ) ∼ GP (Wβ, C(X; η, ρ))
where, β are the parameters related to the mean regression function. C(X; η, ρ) is the
covariance function where the (i, j)th covariance takes the following form


C(X; η, ρ)|i,j = η exp −ρ ||Xi − Xj ||2 + δij J 2
where, ||Xi − Xj ||2 measures the euclidean distance between the p variate confounder sets
of ith and j th patients reflecting the dissimilarity in ith and j th patients’ confounder profiles.
Assuming each regression parameter βk , k = 1(1)p to have prior mean 0 and variance σβ2 ,
the marginal prior covariance between the mean functions of ith and j th subjects can be
expressed as

cov(φ(Xi ), φ(Xj )) = E[φ(Xi )φ(Xj )] − E[φ(Xi )]E[φ(Xj )]
= Eβ [E[φ(Xi )φ(Xj )|β]] − Eβ [E[φ(Xi )|β]]Eβ [E[φ(Xj )|β]]
Noting that,
Eβ [E[φ(Xi )|β]] = Eβ [Wi0 β] = 0
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and
E[φ(Xi )φ(Xj )|β] = cov(φ(Xi ), φ(Xj )|β) + E[φ(Xi )|β]E[φ(Xj )|β]
2

= η exp −ρ ||Xi − Xj ||

2

+ δij J +

p
X

Wik Wjk β 2k

k=1

the marginal prior covariance as in (4.2.4) can be re-expressed as

2

cov(φ(Xi ), φ(Xj )) = η exp −ρ ||Xi − Xj ||

2

+ δij J +

p
X

Wik Wjk σβ2

k=1

In the above formulation, k is the index for the confounders, η > 0 measures the deviation
of the covariance from linearity, ρ > 0 scales the contribution of the distance between the
confounders. The first term makes sure that the covariance is larger for similar profiles and
vice versa. δij corresponds to Kronecker’s delta taking value 1 if i = j and 0 otherwise. J
reflects the amount of jitter, which is similar to noise in regression setting (Bernardo et al.,
1998). A small value of J is usually considered (e.g. J=0.1) to make matrix computation
more stable. This formulation of covariance function should capture complex scenarios.
More general forms of covariance function can certainly be used to capture the variation in
confounder values with the addition of more parameters. However, it comes at the cost of
intensive computation.
Specification of g(A, V; α). For the full specification of the mean function we need to
know the form of g(A, V; α) which can be identified by matching the marginal mean outcome
from (4.1) with that of (4.6). In this context, note that,
E[Y a |X] = Eφ(X)|X [E[Y a |φ(X), X]]
= Eφ(X)|X [g(A, V; α) + φ(X)]
= g(A, V; α) + W0 β
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Averaging out W in the above equation we get
a

Z

(g(A, V; α) + W0 β)dF (W|V)
W
Z
W0 βdF (W|V)
= g(A, V; α) +

E[Y |V] =

(4.7)

W

where, F (W|V) is the distribution of W conditioned on V. Comparing (4.7) with (4.1) will
identify g(A, V; α) as
Z

?0

W0 βdF (W|V)

g(A, V; α) = D α −
W

The specification of g(A, V; α) would require us to compute the integral

R
W

W0 βdF (W|V).

Roy et al. (2016) provided a nonparametric solution of this integral under the assumption of
R
a categorical or a low dimensional V. Specifically, they approximated W WdF (W|V) by
P
1
i:Vi =v Wi = W̃v where, nv is the number of patients having the effect modifier value
nv
v which implies

0

g(A, V; α) ≈ D? α − W̃v0 β.
However, for a continuous V this approximation will not work and we have to resort to a
model based framework. We can consider a parametric or non-parametric model for p(W|V).
As the relationship between W and V is generally unknown, assuming a parametric model
would restrict the model space reducing flexibility of the the final model which is why a
non-parametric specification might be a better alternative. For example, for a univariate W
and V , we can assume the following cubic regression spline as the specification is flexible
enough to capture a wide range of distributions.

f (W |V, δ) =

3
X
j=0

j

δj V +

K
X
k=1

δ3k (V − τvk )3+

53
where, 1, V, . . . , V 3 , (V −τv1 )3+ , . . . , (V −τvK )3+ is cubic p-spline basis, δ = (δ0 , . . . , δ3 , δ31 , . . . , δ3K )
are corresponding coefficients, {τv1 , . . . , τvK } are K pre-specified knot points over the range
of V and x3+ = x3 I(x > 0). For a low dimensional multivariate W and V one can extend this
R
specification to multivariate spline model. Accordingly, we can approximate W WdF (W|V)
by µ(V) = E(W|V) which then determines g(·) as
0

g(A, V; α) ≈ D? α − µ(V)0 β.

Prior Information. We consider a relatively flat prior for the MSM parameters α by
assuming α ∼ N (0, Σπα ) where, Σπα is a diagonal matrix with large values in the diagonal. For
the regression parameter β of the mean function of GP prior, we assume β ∼ N (µπβ , Σπβ ),
with known values of µπβ and Σπβ . We have to keep in mind that the scale parameter ρ
should not be too small as it may destabilize the inversion of the covariance function of
the GP. If the value of ρ is close to zero, it may lead to near singular matrix of covariance
function (Roy et al., 2016). Apart from these, we further assume σy−2 ∼ Gamma(1, 1) and
η ∼ Gamma(1, 1).

4.2.5

Optimal Treatment Decision

The main objective of our method is to allocate the superior treatment choice to the new
patients based on their biomarker profiles and the observed data. The “best” treatment is
determined by the one that corresponds to the treatment option associated with a higher
outcome. Given the pre-treatment variables of the new patient, say X̃ = {X̃1 , X̃2 , . . . , X̃p }0 ,
the optimal treatment, a? can be expressed as a function of X̃

a? = argmax E(Ỹ a |X̃, D)
a
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where, Ỹ a is the potential outcome of the new patient under treatment a.
With that in mind, we develop a Bayesian methodology to predict the mean potential
outcome for the new patient under treatment a for a given X̃ and the observed data D which
we denote as µ̃(a) defined by µ̃(a) = E(Ỹ a |X̃, D) = g(A, Ṽ; α) + φ(X̃). Subsequently to
estimate a? based on the framework we described before. As discussed in section 4.2.5 the
mean posterior predictive potential outcome under treatment a for the new patient can be
formulated as
a

Z

µ̃(a) = E(Ỹ |X̃, D) =

E(Ỹ a |X̃, θ)p(θ|D)dθ

θ

where, θ is the set of unknown parameters µ(·), θ = {α, β, η, ρ, σy }.
The posterior predictive computation is performed in two steps. First, for a = {0, 1}, we
draw N Markov chain Monte Carlo (MCMC) samples of θ, (say, θ ?1 , . . . , θ ?N ) from their joint
posterior distribution p (θ|D). Then, for each drawn MCMC sample of θ ? , we predict the
mean potential outcome of the new patient by plugging in θ ? as a value of θ in E(Ỹ a |X̃, θ).
Accumulating all predicted mean potential outcomes, µ̃1 (a), µ̃2 (a), . . . , µ̃N (a) provide basis
to construct empirical predictive distribution of the mean potential outcomes for the new
patient.
We can estimate the optimal treatment decision in many different ways. For example, we
can choose a? following the recommendation of Gelfand and Ghosh (1998) by minimizing a
suitable posterior predictive loss function. Considering the average loss function, the optimal
treatment can be estimated as
¯
¯
â? = I (µ̃(1)
> µ̃(0))
¯
where, µ̃(a)
=

1
N

PN

i=1

µ̃i (a) with µ̃i (a) being the predicted mean potential outcome of the

new patient under treatment a corresponding to ith MCMC draw.
However, instead of averaging the posterior predictive draws, one could follow a fully
Bayesian approach by considering the notion of stochastic ordering approach where, the
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treatment options are compared for each MCMC draw from the posterior distribution. We
can estimate the probability of potential outcome under treatment 1 to be higher than


potential outcome under treatment 0 by the following formulation, P µ̃(1) > µ̃(0)|X̃, D
P
by P̂ = N1 N
i=1 I(µ̃i (1) > µ̃i (0)). Then the optimal treatment can be derived by putting a
suitable threshold on P̂ . Using an threshold of 0.5 the optimal treatment can be estimated
by



â = I P̂ > 0.5
?

The threshold can be determined from a historical or a biological point of view.

4.2.6

A Numerical Study

We conduct a numerical study to illustrate the performance of the BayesG method under
a simulation setting where the data generation reflects the causal diagram 3.1. We modified
the simulation 1 setting of Zhang et al. (2012b) to include three covariates X1 , X2 , X3 in the
covariate set X. We generate n = 500 observations of {Yi , Xi , Ai }; i = 1, . . . , n where, Xi
are generated from the following model
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The treatments are generated by the following model

A ∼ Bern{logit−1 (−1 + 0.8X12 + 0.8X22 + 0.8X32 )}
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and the outcomes are simulated based on the generated treatments and covariates using

Y ∼ N (µ(A, X), 1)

where, µ(A, X) = 2 − 1.5X32 + 3X1 X3 + A(−0.1 − X1 + X2 ). For the ith patient the true
optimal treatment can be deduced from the outcome model as

A?i = I(Xi1 − Xi2 < −0.1).

Note that, all covariates X1 , X2 , X3 contribute to generate treatments A and outcomes Y
and hence they can be described as confounders. Among them, X1 and X2 have interaction
with A in the outcome model and so the treatment effect will vary for different levels of these
two confounders raising the situation of effect modification which implies V = (X1 , X2 )0 . On
the other hand, X3 affects both treatment and outcome, but is not part of effect modification
making W = X3 .
We apply the BayesG approach in this simulation setting. We assume the true causal
model to be E(Y a |V) = α0 +α1 A+α02 V+α012 AV which we intentionally considered different
from the true data generating model in this case. As W is continuous here, we assume a
cubic p-spline of the form (4.2.4) for the conditional distribution f (W |V) which is required
to compute E(W |V) and consequently the g(·) function. We use the gam function from the
mgcv package in R for this part. We estimate the posterior distributions from the Gibbs
sampling procedure. For the posterior computation, we consider Markov Chain Monte Carlo
(MCMC) methods. We draw 50,000 MCMC samples from the full conditional distribution
of each parameter. Among them 25,000 iterations are considered for burn-in period and the
remaining 25,000 iterations are considered for empirically estimating the posterior predictive
distribution of the potential outcomes.
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Table 4.1: Prediction Measurements of BayesG Method
Accuracy
Sensitivity
Specificity
Mean Median SD Mean Median SD Mean Median SD
0.917
0.93
0.056 0.943
0.965 0.076 0.883
0.92
0.125
We consider three predictive measures (accuracy, sensitivity and specificity) for evaluating
the performance of the BayesG method. The sensitivity is measured by the proportion of
accurate prediction of treatment 1, while the specificity corresponds to the same for treatment
0. The accuracy measurement gives an overview of both these measures by comparing the
predicted optimal treatments to the true ones. Details of these measures are given in the
section 6.3.2.
Table 4.1 summarizes the prediction measurements with mean, median and standard
deviation which are obtained from 100 holdout samples. Section 6.3.1 provides details of
the holdout procedure. From the result table, we see that BayesG has more than 90% overall accuracy for correctly predicting true optimal treatments. Specifically, it predicts true
treatment 1 over 95% of the times while, the other treatment options are correctly predicted around 90% of the times. We compare BayesG with other methods in five simulation
scenarios including the current settings which we detail in chapter 6.

CHAPTER 5
PROPENSITY PREDICTION BASED OPTIMAL
TREATMENT ALLOCATION

In this section, we propose an alternative method (PSBayes) to estimating the optimal
treatment decision for a new patient based on his/her biological profile and clinical information in a binary treatment setting. Similar to the BayesG method, the current approach
also compares the potential outcomes of a new patient under each treatment option. However, as we already have discussed we do not observe the outcome simultaneously for both
treatment options. Instead, we only observe the outcome from the allocated treatment option. Under the consistency assumption (3.2) the observed outcome is the potential outcome
under the given treatment and thus only one of the potential outcomes is observed for each
patient while the other potential outcome remains counterfactual leading to the fact that
each patient has a missing potential outcome corresponding to the treatment option that
(s)he has not received. This motivates us to consider methods from missing data literature
where the objective is to predict the missing potential outcome from the observed predictor
information. We follow an imputation approach in this context for each missing potential
outcome so that we can compare the potential outcomes for the new patient which would
finally direct us to the optimal treatment allocation.
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5.1

5.1.1

Introduction

Framework

As in the previous section, we follow Rubin’s (Rubin, 1978) potential outcome framework.
For a ∈ {0, 1}, we denote Y a as the potential outcome that would be observed if a patient is
administered treatment a. The observed data does not provide information on the potential
outcome Y a under each treatment option a that a patient can have. We only observe a
patient’s outcome when they are exposed to a certain treatment a, not what the patient’s
outcome would have been had (s)he been unexposed to a. As a result, the causal effect due
to the treatment A is not identifiable at an individual level. To link the potential outcome
with the observed outcome, we need to resort to the consistency assumption (3.2) which
states that the observed outcome is essentially the potential outcome under the treatment
option a patient actually receives. It also implies that, under binary treatment settings when
we have two treatment options, say A = 0 and A = 1, either Y 0 or Y 1 is actually observed
while the other one is missing. In general notation, if a patient receives the treatment
A = a, then the potential outcome Y 1−a is missing. Therefore, the treatment variable A can
be assumed to be the response indicator of the potential outcome Y 1 or the missing value
indicator of the potential outcome Y 0 . Therefore, it is evident that estimating individual
level treatment comparison can be posed as a missing data problem where the outcome
of interest is essentially the potential outcome under each treatment option. With this
observation, one approach to make optimal treatment decision, could be by imputing the
potential outcomes for the new patient. In section 3.4.1, we have reviewed a few imputation
methods from the missing data literature where the objective is to unbiasedly estimate the
mean of the outcome having missing observations in MAR setting. In the next section,
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we make a connection between the missing data mechanism and the treatment allocation
procedure and in the following sections we develop the proposed PSBayes methodology for
optimal treatment allocation based on missing data framework.

5.1.2

Treatment Allocation Mechanism

Similar to the missing data mechanism, the treatment assignment can also be classified
into three major groups depending on the conditional distribution of the treatment assignment given the covariates. There is a striking similarity between the patterns of the missing
data mechanism and the treatment assignment mechanism. For example, in completely randomized experiment the treatment assignment probability is pre-determined which is common for all patients. Hence the conditional distribution of the treatment assignment does
not depend on any variable. Denoting the observed covariates by X = (X1 , X2 , . . . , Xp )0 ,
the full conditional distribution of treatment assignment given the potential outcomes and
covariates can be expressed as P (A = a|Y 0 , Y 1 , X, θ) = P (A = a|θ), which is similar to the
setting of ‘missing completely at random’ (MCAR) mechanism.
By the no unmeasured confounders assumption (3.1) which is considered throughout
the dissertation, given all confounders that are responsible for treatment allocation and/or
are associated with outcome, the treatment can be assumed to be randomized among the
subjects with the same observed covariates. This assumption is based on the notion of
conditional exchangeability which can be considered as a special case of ‘missing at random’
(MAR) mechanism. The MAR mechanism corresponds to a more general class where the
conditioning is on the observed part of the outcome Y o along with the covariates, but not on
the unobserved part of the outcome Y m . Mathematically, it implies P (A = a|Y 0 , Y 1 , X, θ) =
P (A = a|Y o , X, θ). On the other hand, in conditional exchangeability assumption, the
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treatment assignment only depends on the observed value of the covariates i.e. P (A =
a|Y 0 , Y 1 , X, θ) = P (A = a|X, θ).
In some situations, the treatments are administered not only based on the observed covariates, but the potential outcomes also play role in deciding the best treatment. In such
cases, the treatment assignment mechanism depends on both the observed and missing information i.e. P (A = a|Y 0 , Y 1 , X, θ) = P (A = a|Y m , Y o , X, θ), where Y m is the unobserved
part of the outcome. It is very similar to the scenario of ‘not missing at random’ (NMAR)
where the missing indicator not only depends on the observed data but also on the missing
data.
Due to the fair similarity between the frameworks of causal inference and missing data
analysis, two common approaches are often pursued to handle missing data or treatment
allocation mechanism: weighting and imputation. In weighting methods such as inverse
probability weighting (IPWE) or augmented inverse probability weighting (AIPWE), a parametric or semi-parametric model is often assumed where the weights are calculated based
on the probability of allocation to a certain treatment group. The entire method usually
consists of two stages where in the first stage, a propensity score model is employed to fit the
probability of treatment allocation P (A = a|X, γ) on the observed covariates assuming the
treatment decision is driven by the whole set of covariates X. A weighted analysis is then
carried out to model the outcome Y based on the covariates X where the weight is a function
of the observed propensity score P̂ (A|X, γ̂). On the other hand, in the imputation method,
a function of the observed covariates is often used to model the outcome and the same model
is employed to predict the missing outcome given a set of covariates. Although, both approaches are mathematically interconnected, they often originate from different perspectives
and are implemented differently.
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5.1.3

Propensity Score

In observational studies, treatment assignment is usually driven by patient characteristic(s) and the response is observed after a treatment is administered. Hence, there is high
likelihood that the treatment effect gets confounded with the effect of the characteristic(s)
which is associated with treatment selection. In order to remove the confounding bias in
treatment effect estimation, it is important to adjust for the association between the treatment and other covariates.
In randomized clinical trial, the treatment assignment mechanism is pre-determined.
However, in observational studies, the probability of receiving a certain treatment, also
known as propensity score is unknown and is estimated by fitting a model to the treatment
based on the relevant covariates. For a binary treatment A, the following model can be used
to fit the propensity of receiving A = 1.

logit{P (A = 1|X, γ)} = Xγ

(5.1)

Instead of logit, one might also use the probit link as

Φ−1 (P (A = 1|X, γ)) = Xγ

(5.2)

Rosenbaum and Rubin (1983) showed that the propensity score has a key balancing
property in the sense that given a value of the propensity score, the treatment choice does
not depend on the covariates. Thus the treatment assignment mechanism can be assumed
to be completely randomized within the group of subjects having similar PS values. Mathe-
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matically, the conditional independence between treatments and covariates can be expressed
as
A⊥
⊥ X | e(X).
where, e(X) is the conditional probability of assignment to treatment 1 given the covariates
i.e. e(X) = P (A = 1|X).
Propensity score can be used as a matching tool to remove imbalance in the confounder
distribution among the treated and untreated. Exploiting this feature, propensity score is
commonly used in both weighting and imputation methods to remove or adjust confounding
bias in causal inference literature. Robins (1998b,c) introduced a weighted analysis approach
to estimate the treatment causal effect where the weight of each subject is obtained by the
inverse probability of the treatment, ŵ(X) = P̂ (A = a|X)−1 . For the subjects in treatment
1 group, ŵ(X) = ê(X)−1 and for subjects receiving treatment 0, ŵ(X) = (1 − ê(X))−1 .
The estimated weights create a pseudo population free of treatment confounders, which
allows to unbiasedly estimate causal parameters in a regression setting. The weighting
methods are very popular in causal inference and survey sampling literature. However, one
major limitation of such method is that, due to its inverse formulation, it may assign large
weight to a subject with small propensity score yielding estimates with large variance (Little
and Rubin, 2014).
Apart from the weighting method, several approaches have been proposed to include
weights in the imputation model for predicting nonresponse in the missing data setting.
For example, the linear in the weight prediction (LWP) method (Scharfstein et al., 1999;
Bang and Robins, 2005; Zhang and Little, 2009) includes the weight as a linear term in the
imputation model as follows


(Y |X; β) ∼ N g (X; β) + αŵ(X), σ 2 .
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In the proposed methodology, we adopt a similar approach to imputation model specification. But instead of using the inverse function, we include the propensity score in the
imputation model through a Bayesian p-spline function resulting in a more robust specification of the mean model. This approach avoids weighting which may result in highly variable
estimates for small number of cases. Also, under the Bayesian paradigm PSBayes allows for
small sample inferences which can aptly reflect uncertainty in imputing potential outcomes.
In the next subsection, we discuss p-spline model for a complete data. In the later sections
we describe the proposed likelihood model in the light of Bayesian p-spline regression.

5.1.4

P-Spline Model

Berry et al. (2002) proposed a regression penalized spline (P-spline) model for complete
data under both frequentist and Bayesian settings. Consider a simple scenario where there
are two sets of vectors - Y = (Y1 , Y2 , . . . , Yn )0 and X = (X1 , X2 , . . . , Xn )0 . Assume that,
ith components of Y and X are connected by Yi = m(Xi ) + i , where i is a random error
with mean 0 and variance σ2 . Let g be a P-spline approximator of m, such that the squared
Pn
2
error distance
i=1 {m(Xi ) − g(Xi )} is minimized. Under the assumption that m is a
smooth function, m(cdot) can be well approximated by g(·). Following the notations from
Berry et al. (2002) the regression P-spline model g can be specified by g(X) = B(X)0 β
where, B(X) = (B1 (X), B2 (X), . . . , BN (X))0 is a N ≤ n dimensional spline basis with
corresponding regression coefficients β = (β1 , β2 , . . . , βN )0 . Under this framework, for a
given value of the smoothing parameter α, the penalized least square estimator β̂ can be
obtained by minimizing
n
X
i=1

{Yi − B(Xi )0 β}2 + αβ 0 Dβ,
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and is given by
β̂(α) = (B 0 B + αD)

−1

B0 Y

where, B = {B (X1 ) , B (X2 ) , . . . , B (Xn )}0 .
One convenient basis function considers a p degree polynomial of the form B(x) =
0

(1, x, x2 , . . . , xp , (x − t1 )p+ , . . . , (x − tK )p+ ) , where t1 , t2 , . . . , tK are K fixed knots, preferably
chosen at the quantiles of X. In this specification, the regression coefficients can be divided
into two parts - the first part of regression coefficients β 1 = (β1 , . . . , β(p+1) )0 corresponds
to monomial basis functions whereas, the second part β 2 = (β(p+2) , . . . , βN )0 represents the
jumps in the pth derivative of g(X) at the knots, where N = K + p + 1. To penalize these
jumps, Berry et al. (2002) proposed D matrix as N ×N diagonal matrix with p+1 zeroes folP
2
lowed by K ones along the diagonal so that the roughness penalty term β 0 Dβ = K
j=1 β1+p+j
yields the sum of squared jumps.
Under the Bayesian setting, the same specification can be achieved from the following
formulation by An and Little (2008)




Y|β, σβ2 2 , σy2 , X1 , X2 ∼ N X1 β 1 + X2 β 2 , σy2 In .

where,





X1 = 




···

X1p

1 X2 X22 · · ·
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β 0 = (β 01 , β 02 ) where β 1 is the fixed effect and β 2 is the random effect with


β 2 |σβ2 2




∼N


σβ22
0,
IK .
α

where, α is the tuning parameter as in the frequentist setting. The prior distributions of the


2
2
unspecified parameters denoted by θ = β 1 , σβ2 , σy are given by
 

π (β 1 ) ∝ 1, π σβ2 2 ∼ Inv-Gamma (aβ2 , bβ2 ) , π σy2 ∼ Inv-Gamma (a , b )
Under this specification, the mean of the posterior distribution of β conditional on σy2 and
α yields the same penalized least square estimator as obtained from the frequentist specification.

5.2

5.2.1

Method

Framework

Suppose we observe a group of n patients with p covariates and the covariate matrix is
denoted by X = (X1 , X2 , . . . , Xn )0 , where Xi = (Xi1 , Xi2 , . . . , Xip )0 is the covariate vector
of ith patient. We also observe the treatments the patients have received and the observed
treatment vector is denoted by A where each treatment can only be 0 or 1. Lastly, the
response vector of all patients is denoted by Y. For the new patient, we only have information
on his/her covariates denoted as X̃. For simplicity, we assume that there is no missing
information within the observed dataset D = (X, A, Y).
The potential outcome under a treatment a is denoted by Y a . Each patient has two potential outcomes Y 0 and Y 1 . Under the consistency assumption, the observed outcome can
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Table 5.1: Observed and missing potential outcome under each treatment
X
X1
X2
..
.

A
0
0
..
.

Y0
Y1
Y2
..
.

Y1
−
−
..
.

Xr
Xr+1
..
.

0
1
..
.

Yr
−
..
.

−
Yr+1
..
.

Xn
X̃

1
−

−
−

Yn
−

be expressed in terms of potential outcome and the treatment option (s)he has been administered by Y = Y 0 (1−a)+Y 1 (a), which implies one of the potential outcome corresponding to
the treatment that (s)he has received is observed and the other one is missing which implies
the treatment indicator A plays the role of the response indicator for the potential outcome
Y 1 , as under the consistency assumption, Y 1 is observed when A = 1 and is missing when
A = 0.
Suppose, in the dataset D, first r out of n patients received treatment 0 and the remaining n − r patients received treatment 1. Then from the data point of view, it implies that
the potential outcome Y 0 is observed for the first r patients while Y 1 is missing, whereas for
the remaining n − r patients, the potential outcome Y 1 is observed and Y 0 is counterfactual.
For the new patient, both Y 0 and Y 1 are missing. This observed connection between treatment allocation and missing data mechanism is visually illustrated in table 5.2.1. Although
the observed data does not have any missing information, under our assumption, the full
data comprised of the potential outcomes denoted by DF = (X, A, Y0 , Y1 ) have missing
information due to unobserved counterfactual outcomes.
Motivated by observing the close relationship between the treatment assignment and
the missing data mechanism, we build the PSBayes methodology within the missing data
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framework. Zhang and Little (2009) discussed several regression based imputation methods
from the missing data literature where the objective was to estimate the mean of a variable
with missing observation. By drawing analogy to the potential outcome settings in causal
inference, those methods can also be applied to the framework we are considering here. For
example, the imputation model for the potential outcome can be formulated by a parametric
model as

a

Y = β0a +

p
X

βja Xj + 

j=1

where, β0a , β1a , . . . , βpa are the regression coefficients characterizing effect of covariates on the
potential outcome under treatment a. One can estimate βja based on the observed outcome
by the frequentist or Bayesian approach and predict the missing counterfactual outcome
for an observed set of covariates. Then one can estimate the mean potential outcome by
combining observed and predicted potential outcomes. This method is very effective under
the correct model specification, however performs poorly otherwise.
One way to avoid this limitation is to consider a robust mean function in the model
specification similar to the linear in weight prediction (LWP) method (Scharfstein et al.,
1999; Bang and Robins, 2005; Zhang and Little, 2009) which includes inverse propensity
score as an additive term in the model. Robustness in the imputation model specification
can also be achieved by relaxing its parametric specification. Semi-parametric and nonparametric methods have the ability to capture the nonlinear relationship between model
variables.
In presence of a single predictor X, we can follow Ruppert et al. (2003); Eilers and Marx
(1996) to specify the imputation model based on the penalized spline model Y a = s(X, βa )+
with truncated polynomial basis of degree q as follows
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s(X, β a ) =

q
X
j=0

j

βja X +

K
X

βqka (X − tk )q+

(5.3)

k=1

where, 1, X, X 2 , . . . , X q , (X − t1 )q+ , . . . , (X − tK )q+ is truncated power basis of degree q, similarly defined as in the previous section and t1 < · · · < tK are the fixed knots on the range
of X.
The model above is robust and very effective to capture the non-linear relationship between the potential outcome and the predictors. However, there are two potential shortcomings of this method. First, as the observational study entails confounding bias due to
the non-randomized treatment allocation, it is very important to adjust for the mismatch in
the confounder distribution among the treatment groups, which the method above fails to
address. Second, in presence of more than one predictor, which is a very common scenario,
one would extend the model by considering multivariate spline in the imputation model. But
such approach would be subject to the curse of dimensionality in the high dimensional setting
and fitting a nonparametric regression model would be difficult under this circumstance.
The penalized spline of propensity prediction (PSPP) method (Little and An, 2004;
Zhang and Little, 2009) overcomes both of these limitations by (1) employing a propensity
score model to fit the treatment based on the covariates and by (2) restricting the spline in
the penalized spline model (5.3) to the propensity score. PSPP model has three variants (1) maximum likelihood (PSPP-ML): parameters are estimated using maximum likelihood
method and the information matrix or bootstrap approach is employed to obtain the standard
error, (2) Bayes (PSPP-B): posterior distribution is used to draw parameters and inference
is based on standard Bayesian approach and (3) multiple imputation (PSPP-MI): missing
values are imputed multiple times and Rubin’s (1987) MI combining method is used for
drawing inference. We base our method on PSPP framework and develop a novel approach
to predict the optimal treatment of the new patient based on the imputed missing potential
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outcomes. In addition, Bayesian posterior predictive inference is employed for quantifying
the uncertainty in estimating the missing outcomes.

5.2.2

Bayesian Inference

Likelihood Model. We employ a joint modeling framework consisting of two parts. In
the first part, we consider a propensity score (PS) model where we fit the propensity of each
treatment assignment based on observed covariates. Specifically, we assume the following
PS model for the distribution of A given the observed covariates X = (X1 , X2 , . . . , Xp )0 and
the regression parameters γ

logit (P (A = 1|X, γ)) = X0 γ = e(X, γ) (say)

(5.4)

The regression method depends on the class of treatment variable. For the scenario of more
than one treatment, one could also use a different regression method such as a polytomous
regression model.
The second part of the model is developed in the outcome stage where we consider two
separate models for the potential outcomes Y a under both treatment 0 and 1. For each
treatment group, we fit the potential outcomes Y a based on the observed covariates X and
the logit of the propensity of belonging to a particular treatment group a, say ea (X, γ). So,
for a patient receiving treatment 1, e1 (X, γ) = e(X, γ), but for a patient with treatment
0, e0 (X, γ) = logit(1 − logit−1 (e(X, γ))). Including the propensity score in the outcome
model not only facilitates adjustment for the confounding bias, but also addresses the issue
arising from high dimensionality, in case there are many predictors. However, the true
relationship between the propensity score and the outcome is not known. Following Zhang
and Little (2009), we include a non-parametric spline regression function of ea (X, γ) in the
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mean function µ(·) of potential outcome model under treatment a. Formally, the outcome
model can be expressed in the following way,

(Y a |X; θ a ) = µ(X, A = a; θ a ) + 

(5.5)

where,
µ(X, A = a; θ a ) = s(ea (X, γ); αa ) + g (ea (X, γ), X2 , . . . , Xp ; β a )
with θ a being all unknown parameters in the model. s(ea (X, γ); αa ) is a penalized spline with
fixed knots and parameters αa , g(·) is an augmented parametric function of other covariates
with parameters β a .  is the normal random error associated with the outcome model such
that  ∼ N (0, σy2 ). Note that, including the propensity score along with other covariates in
g(·) would involve the issue of multicollinearity. Therefore, without loss of generality, X1 is
excluded from g(·). For a ∈ {0, 1} we assume the following q degree polynomial basis for
s(ea ; αa ),

s(ea (X, γ); αa ) =

q
X
j=0

j

α1ja ea (X, γ) +

K
X

α2ka (ea (X, γ) − tka )q+

(5.6)

k=1

where, αa = (α01a , α02a )0 with α1a = (α10a , α11a , . . . , α1qa )0 representing the fixed effect parameters and α2a = (α21a , α22a , . . . , α2Ka )0 denoting random effect parameters with α2a ∼

NK 0, σα2 2 IK . t1a < t2a < · · · < tKa are K knots selected on the range of ea (X, γ) and the
truncated power function is defined as f (x) = xq+ = xq I(x > 0).
For the parametric function g(·) we assume a linear form

g(ea (X, γ), X2 , . . . , Xp ; β a ) = β1a ea (X, γ) +

p
X
j=2

βja Xj
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where, β a = (β1a , . . . , βpa )0 are fixed effects. This specification only allows to adjust for the
main effects of the covariates. However, if necessary, interaction between ea (X, γ) and the
covariates can also be included in the model.
Prior Specification. For the propensity score model parameters, γ, we assume flat

normal priors γ ∼ Np+1 µπγ , Σπγ where, µπγ and Σπγ are pre-specified hyper-parameters.
Specifically, we chose µπγ = 0 and Σπγ = 103 Ip+1 . Following the prior specifications in the
Bayesian p-spline regression model (Berry et al., 2002; An and Little, 2008), we assume
a flat prior for the coefficients in monomial basis part of the spline function, α1a such
that α1a ∝ 1. For the parametric function g(·) we also assume a normal prior for the
coefficients, β with high variance values. Specifically, we consider β ∼ Np (0, 103 Ip ). We
assume flat priors for σα−22 , the precision parameter of the random basis coefficients in the
truncated part of the spline function s(·), and also for σy−2 , the precision parameter of the
potential outcome imputation model. Specifically, we chose σα−22 ∼ Gamma(0.001, 0.001) and
σy−2 ∼ Gamma(0.001, 0.001).

5.2.3

Optimal Treatment Allocation

The optimal treatments for PSBayes method can be estimated in the similar fashion
as described for the BayesG approach. We construct a Bayesian methodology to predict
the mean potential outcome for the new patient under treatment a for a given X̃ and the
observed data D which is formally expressed as µ̃(a) = E(Y a |X̃, D) = s(ea (X̃, γ); αa ) +


g ea (X̃, γ), X2 , . . . , Xp ; β a and subsequently to estimate a? based on the framework we
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described before. As discussed in section 4.2.5 the mean posterior predictive potential outcome under treatment a for the new patient can be formulated as

a

Z

µ̃(a) = E(Ỹ |X̃, D) =

E(Ỹ a |X̃, θ a )p(θ a |D)dθ a

θa

where, θ a is the set of unknown parameters in the mean function µ(·) for treatment group
a, θ a = {γ, α1a , α2a , β a , σα−22a , σy−2 }.
The posterior predictive computation can be performed similarly as is done for BayesG
approach. We can estimate the optimal treatment decision in many different ways. We
follow a fully Bayesian approach where, similar to the notion of stochastic ordering, we
compare the treatment options for each MCMC draw from the posterior distribution. We
estimate the probability of potential outcome under treatment 1 to be higher than potential


outcome under treatment 0 by the following formulation, P µ̃(1) > µ̃(0)|X̃, D by P̂ =
PN
1
i=1 I(µ̃i (1) > µ̃i (0)). Then the optimal treatment can be derived by putting a suitable
N
threshold on P̂ . Using an threshold of 0.5 the optimal treatment can be estimated by


â? = I P̂ > 0.5 .

5.3

A Bayesian Nonparametric Specification

The OS model of the PSBayes method estimates regression models for the potential
outcome Y a on (1) a spline of the logit of the propensity score of treatment group a and
(2) a linear function of other covariates that are predictive of Y and we assume the error
distribution to be normal. Despite specifying a nonparametric function for the mean model,
this formulation would be able to capture only a specific class of true models where the mean
function is additive in predictors with an unimodal symmetric outcome distribution as we
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assume a linear formulation of the parametric g(·) function with gaussian error distribution.
However, a flexible non-parametric specification of the outcome distribution is often desired,
particularly in presence of multiple modes or skewness. Keeping this in mind, we develop a
flexible Bayesian nonparametric model (BNP) based on Dependent Dirichlet Process (DDP)
(MacEachern, 2000) for the potential outcome Y a . Our specification is similar to that of
Roy et al. (2016); Xu et al. (2016) in the BNP part, but their objectives were different from
ours.
To be specific, let us assume that Y a |X ∼ F (·|A, X). Unless a parametric setup is
specified, F belongs to a family of probability models which sets the basis of nonparametric
inference. Under the Bayesian paradigm, we assume a prior distribution on F (·|A, X) in
the form of π(F (·|A, X)) which is a probability model for the infinite dimensional F (·|A, X).
Here we specifically consider a Dirichlet Process (DP) prior for F (·|A, X). Following Xu et al.
(2016) we first start the DDP specification with a model for a discrete model distribution
G(·). Then we use a Gaussian kernel to specify a DP prior model for the continuous random
distribution F (·). Next, we specify the mean of the Gaussian kernels through the mean
function to extend it to the prior distribution of F (·|A, X) (5.5). In the following subsections
we briefly review the Dirichlet Process Prior models and detail the construction of G(·), F (·)
and F (·|A, X) following the frameworks of Müller and Rodriguez (2013); Müller et al. (2016).

5.3.1

Dependent Dirichlet Process

Dirichlet Process. Dirichlet process prior is one of the very popular BNP models which
was introduced by Ferguson (1973) in the context of prior distribution on the space of random probability measures (RPM). Formally, let S be a space and let B be a σ field of subsets
of S. Further let G0 be a probability measure on (S, B) and let M > 0. Then G, defined on
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(S, B) is a Dirichlet process with parameters (M, G0 ) if it assigns probability G(B) to every
measurable set B such that for each (measurable) finite partition {B1 , B2 , . . . , Bk } of S, the
joint distribution of the random probability vector {G(B1 ), G(B2 ), . . . , G(Bk )} has a Dirichlet distribution with parameters {M G0 (B1 ), M G0 (B2 ), . . . , M G0 (Bk )}. The parameter M
is called the concentration or precision parameter, while G0 is known as the base measure of
the DP. For a large M , G is highly concentrated about G0 and as M → ∞ the DP process
G converges to G0 .
There are many important properties of the DP. First, due to its discrete nature, G(·)
P
can be expressed as a weighted sum of point masses such as G(·) = ∞
h=1 wh δθh (·) where,
δθh (·) denote point mass at θh and wh is the corresponding probability weight. As we will
discuss shortly, this specification leads to a specific characterization of DP known as the stick
breaking construction. Another important property is that the closure of the support of DP
includes the space of all distributions with the same support as the base measure G0 (Müller
et al., 2016), which is why the DP prior model is extremely useful for density estimation
under iid sampling from an unknown distribution (Ishwaran and James, 2001).
Stick Breaking Construction. Sethuraman (1994) provided an alternative specificaP
tion of the DP model which is based on its discrete nature such as G(·) = ∞
h=1 wh δθh (·)
where, θ1 , θ2 , . . . are iid draws from the base measure G0 and wh is defined as wh =
Q
iid
vh l<h (1 − vl ) with vh ∼ Beta(1, M ). The draw of wh can be imagined as repeatedly breaking a fraction vh part of from a stick of originally unit length. Hence this representation
was coined as ”stick breaking” construction. This specification is useful to generate random
samples from a DP prior.
Dirichlet Process Mixture. The DP model G is discrete with probability 1. For continuous density estimation, this limitation can be avoided by specifying continuous kernels
in place of point mass δθh (·) i.e. by adding a convolution with a continuous kernel to the
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discrete distribution G (Ferguson, 1983; Lo, 1984; Escobar, 1990, 1994; Escobar and West,
1995). The Dirichlet Process mixture (DPM) prior on F can be semi-parametrically represented as
Z
F (·) =

p(·|θ)G(dθ), G ∼ DP(M, G0 )

(5.7)

where, p(·|θ) is a parametric distribution characterized by finite dimensional parameter θ
and G(·) is a probability distribution on θ. Such mixture representation can constitute a
rich family of distributions. For example, Lo (1984) illustrated that a DP location-scale
mixture of normals with mean µ and variance σ 2 ,
Z
F (·) =

N (·|µ, σ 2 )G(dµ, dσ 2 ), G ∼ DP(M, G0 )

has support on the space of all absolutely continuous distributions. Furthermore, a mixture
with respect to location and scale θ = (µ, σ) in a kernel k(y|µ, σ) = σ −1 k((y − µ)/σ) for a
fixed density k,
Z
F (·) =

σ −1 k(·|µ, σ)G(dµ, dσ), G ∼ DP(M, G0 )

approximates any density in the L1 sense under some mild condition. Similarly, a mixture
of uniform distributions with symmetric support around 0,
Z
F (·) =

U (·| − θ, θ)G(dθ), G ∼ DP(M, G0 )

where, U (·| − θ, θ) is a density of an uniform random variable on [−θ, θ], has full support on
the space of all unimodal symmetric distributions (Müller and Rodriguez, 2013).
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The representation in (5.7) can be alternatively characterized with the help of stick
breaking construction of the Dirichlet process as

F (·) =

∞
X

wh p(·|θh ).

h=1

This representation essentially presents DPM as a discrete mixture model where, p(·|θh ) is
the parametric distribution of the hth component of the mixture characterized by θh with
Q
wh being the corresponding probability weight, θh ∼ G0 , wh = vh h0 <h {1 − vh0 } and vh ∼
Beta(1, M ). For example, if we use a normal kernel N (·|µ, σ) in place of the parametric
distribution p(·|θ), the DPM with location mixture can be expressed as

F (·) =

∞
X

wh N (·|µh , σ).

h=1

where, µh ∼ G0 and other parameters are same as before. This normal mixture characterization is very useful for density estimation under iid sampling from an unknown distribution
and it provides a good fit to the data from a wide range of scenarios as virtually any distribution can be closely approximated by the mixture of normal distributions (Ishwaran and
James, 2001).
Dependent Dirichlet Process. In the context of non-parametric regression, we are
often interested in inference for a family of probability models indexed by the covariate x,
F = {F (·|x), x ∈ X}. For BNP regression with non-parametric mean function specification,
one would consider a mixture of a standard parametric residual distribution and a BNP
prior on the mean function, whereas a full non-parametric regression would put the BNP
prior on the family of probability models, F (Müller and Rodriguez, 2013). In this context,
MacEachern (2000) extended the DP prior for a single random probability measure to the
desired family of random probability measures p(F (·|x), x ∈ X) on the F space which is
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named as Dependent Dirichlet Process (DDP). The characterization of the DDP follows the
stick breaking representation of the DP. Specifically in the regression setting, a DP prior for
F (·|x) can be expressed as
F (·|x) =

∞
X

wh p(·|θh (x)).

(5.8)

h=1

θh (x) ∼ G?x , independent across h where G?x is the base measure characterized by x and
Q
wh = vh h0 <h {1 − vh0 } with vh ∼ Beta(1, M ). Marginalizing over θh (x), this specification
ensures that F (·|x) ∼ DP(G?x , M ). One key feature of this characterization is that it allows
users to introduce dependence of θh (x) across x and by imposing a dependent prior on
{θh (x)} one can create dependent random probability measures F (·|x, x ∈ X) (Müller and
Rodriguez, 2013). MacEachern (2000) proposed a Gaussian Process prior on {θh (x), x ∈ X}
as a default choice. However, other models can also be used. The default specification of
DDP model (5.8) is sometimes called as variable location DDP as only locations θh (x) are
characterized by x. Generalizing this idea, the weights wh or both weights and locations
could be indexed with x too, leading to variable weight and location DDP (Müller and
Rodriguez, 2013).

5.3.2

Proposed Specification

Likelihood Model. Our objective is to propose a flexible structure for the imputation
model so that it can provide a good fit to a wide range of situations. To this direction,
we propose a Bayesian semiparametric specification (PSBayes-DDP) for the OS part in our
likelihood model. Our proposed model offers flexibility both in terms of the mean function
and also in the residual distribution.
Similar to the original PSBayes methodology, here we stick to the joint modeling framework with PS and OS models. For the PS model involving the distribution of A given the
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observed covariates X = (X1 , X2 , . . . , Xp )0 and the regression parameters γ we assume the
same specification (5.4) as before.
On the contrary to the previously proposed OS model, here we assume (Y a |X) ∼
F (y|X, A), where F (·|X, A) belongs to a family of probability models F = {F (·|x, A); x ∈
X, A ∈ {0, 1}} characterized by x and a. On the basis of the previous discussion, we can
impose a dependent DP mixture prior on F (y a |X) to include the regression on covariates
and treatment. Following the stick breaking construction, we specify

F (Y a |X) =

∞
X

wh N (Y ; µh (X, A), σy2 )

(5.9)

h=1

where, wh ; h = 1, . . . , ∞ are the DP mixture weights, µh (X, A) is a function of treatment
and covariates which endows the hth component of the mixture with the same formulation
of the mean outcome model as we specified before. In formal notations µh (·) is defined as
follows,
µh (X, A) = s(ea (X, γ); αha ) + g ea (X, γ), X2 , . . . , Xp ; β ha



where, s(ea (X, γ); αha ) is the similarly defined penalized spline with fixed knots and parameters and αha , g(·) is an augmented parametric function of other covariates with parameters
β ha corresponding to hth component of the mixture. Note that, the formulation in (5.9)
provides us with an infinite mixture of normals, with weight wh corresponding to the hth
P
mixture component such that ∞
h=1 wh = 1 and is very flexible to deal with situations like
multiple modes or skewness in the outcome distribution (Roy et al., 2016).
Similar to the original specification, for a ∈ {0, 1} we assume the following q degree
polynomial basis for s(ea ; αah ),

s(ea (X, γ); αha )

=

q
X
j=0

h
α1ja
ea (X, γ)j

+

K
X
k=1

h
α2ka
(ea (X, γ) − tka )q+

(5.10)
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where, αha =



0


0 0

0
h
h
h
with αh1a = α10a
, α11a
, . . . , α1qa
representing the fixed effect
0
h
h
h
= α21a
, α22a
, . . . , α2Ka
denoting random effect parameters with αh2a ∼

αh1a , αh2a

parameters and αh2a

NK 0, σα2 2 IK . t1a < t2a < · · · < tKa are K knots selected similarly on the range of ea (X, γ).
For the parametric function g(·) we assume a linear form

g(ea (X, γ), X2 , . . . , Xp ; β ha )

=

h
β1a
ea (X, γ)

+

p
X

h
βja
Xj

j=2

h
h
where, β ha = β1a
, . . . , βpa

0

are fixed effects. This specification only allows to adjust for the

main effects of the covariates.
Prior Specification. The prior distribution for the weights, wh = vh

Q

h0 <h (1

− vh0 ) is

specified as vh ∼ Beta(1, M ), M being the precision parameter. For the prior distribution
of M , we assume M ∼ Inv-Gamma(1, 1) following the suggestion by Roy et al. (2016). This
prior has longer tail than Gamma(1, 1) and provides stability in posterior computation. For
the propensity score model parameters, we assume same priors as before. We also chose
same prior for each component of OS parameters. Specifically, we assume αh1a ∝ 1. For
the parametric function g(·) we also assume β h ∼ Np (0, 103 Ip ). All the precision parameter
priors are remained same.

5.3.3

Optimal Treatment Allocation

In the proposed PSBayes-DDP methodology, the potential outcome is expressed as a
discrete mixture of infinitely many normal distributions. We develop a Bayesian methodology
to predict Ỹ a and subsequently to estimate a? based on the framework we described before.
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As discussed in section 4.2.5 the posterior predictive potential outcome under treatment a
for the new patient can be formulated as




a

Z

p Ỹ |X̃, D =



a



p Ỹ |θ a , X̃ p (θ a |D) dθ a
θa

where, θ a is the set of unknown parameters for treatment group a, θ a = {γ, α1a , α2a , β, σα−22a , σy−2 }.
For the posterior predictive computation, first we draw N MCMC samples of θ a , (say,
θ ?a1 , . . . , θ ?aN ) for a = {0, 1}, from their joint posterior distribution p (θ a |D). Then, for
each drawn MCMC sample of θ ?a , we impute the potential outcome of the new patient


∗
say, Ỹ a by drawing a sample from p Ỹ a |θ a , X̃ . Given all imputed potential outcomes,
∗

∗

∗

Ỹ1a , Ỹ2a , . . . , ỸNa we can construct empirical predictive distribution of the potential outcomes
for the new patient.
Based on the empirical posterior predictive distribution of the potential outcomes, we
can estimate the optimal treatment allocation in many different ways. For example, we
can choose a? following the recommendation of Gelfand and Ghosh (1998) by minimizing a
suitable posterior predictive loss function. Considering the average loss function, it can be
formulated as


a? = I E(Ỹ 1 |X̃, D) > E(Ỹ 0 |X̃, D)
which can be estimated by
 ∗

∗
â? = I Ỹ¯ 1 > Ỹ¯ 0
where, Ỹ¯ a =

1
N

PN

i=1

∗

∗

Ỹia with Ỹia being the imputed potential outcome under treatment a

of the new patient corresponding to ith MCMC draw.
Based on the empirical posterior predictive distribution of the potential outcomes, we
adopt a fully Bayesian stochastic ordering appraoch which allows us to compare the treatment options in each draw and estimate the probability of potential outcome under treat-
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ment 1 to be higher than potential outcome under treatment 0, P Ỹ 1 > Ỹ 0 |X̃, D by
P
∗
1∗
> Ỹi0 ). Then the optimal treatment can be derived by a suitable
P̂ = N1 N
i=1 I(Ỹi
threshold on P̂ . Using an threshold of 0.5 the optimal treatment can be estimated by


â? = I P̂ > 0.5 .

5.4

Model Feedback

5.4.1

Introduction

In observational studies treatments are selected based on the patient characteristics. Because of the non-randomized allocation, methods proposed in observational study literature
often consider treatment as stochastic variable and postulate the propensity score model
on the treatment surface to analyze the dependence of treatment allocation on observed
covariates. In point treatment settings, the propensity score (PS) model can be employed
to estimate the probability of allocation of certain treatment option as a function of the
observed covariates. In randomized study, treatment comparison is direct as the distribution
of patient covariates in the treatment groups are fairly similar. However, in non randomized
design such as observational studies direct comparison between treatment groups may not be
feasible since the patient characteristics differ across different treatment groups. Originating
from survey sampling methods, there are two major streams of approaches to treatment
comparison in observational studies. Among them, one group of methods rely on a two
stage approach where the analysis is carried out in two stages. In the first stage, a propensity score model is fitted to predict the probability of receiving certain treatment option for
each patient. Typically a logistic regression model of the treatment variable based on the
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measured confounders is employed for this purpose. In the second stage of the method various approaches are proposed in the literature depending on the objective of the study. To
adjust for confounding by the measured covariates Rosenbaum and Rubin (1983) advocated
stratification of patients based on quantiles of the PS values. In stead of directly comparing
the outcomes between different treatment groups, the outcomes from treatment groups are
matched within same PS quantile values. In the regression setting, a regression model is employed on the response surface to compare the treatment options by matching the outcomes
from subjects with similar PS values. In the context of treatment causal effect estimation, a
weighted regression analysis is often performed on the response surface in the second stage
where the weights are obtained from the fitted PS values. A second group of methods such
as the linear weight in prediction (LWP) (Scharfstein et al., 1999; Bang and Robins, 2005)
similarly use PS model to estimate the propensity score, but instead of performing a weighted
analysis, they treat the weights as covariate and thus adjusts for covariate imbalance. No
matter what weighting method is used, in the traditional frequentist approach the first stage
and second stage models are fitted sequentially where the estimated PS values are treated
as fixed quantities in the second stage.
On the other hand, the Bayesian methods have a natural appeal in this setting as combining two separate models into a joint likelihood model would facilitate simultaneous estimation of PS and OS models. A major advantage of the Bayesian methods is that by
jointly modeling the treatment-covariate and outcome-covariate-treatment associations the
uncertainty in propensity score estimation can be incorporated in the OS stage, whereas
in frequentist counterpart treatment effect estimation does not acknowledge uncertainty in
propensity score which might make falsely precise confidence interval for treatment effect.
McCandless et al. (2009) proposed one such method where the propensity score is treated
as a latent variable. The striking feature of their method is that the posterior estimation
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of marginal treatment effect incorporates treatment selection uncertainty which is averaged
out over the latent variable in the outcome stage of the model.
One implicit characteristic of the joint modeling framework in the Bayesian PS estimation
is that the posterior inference allows the PS parameters to get updated by the OS model
information. This notion, known as “model feedback” (Zigler et al., 2013) from OS to PS
model has raised some concerns against the use of Bayesian method in the propensity score
setting. Rubin (2007, 2008) argued that PS models are implemented to approximate the
design of randomized study and should be completely independent of the outcome. Zigler
et al. (2013) demonstrated that the flow of information from OS model to PS model weakens
the property of PS model to adjust for confounding which leads to biased estimate of the
treatment effect. However, the issue is partially addressed if we include individual covariates
in the outcome model in addition to PS adjustment.

5.4.2

An Example

Zigler et al. (2013) illustrated the effect of model feedback on treatment causal effect
estimation using a simple example with binary treatment and binary outcome in the regression setting similar to that of (McCandless et al., 2009). For A and Y , we follow the same
notations as before, but for X, we only use bold font when it includes patients’ information.
Here also, we consider A ∈ {0, 1}. Unlike Zigler et al. (2013), we are assuming the outcome
variable to have continuous observations. X denotes a n × p covariate matrix containing
information on n patients with p covariates. A denotes the treatment vector of n patients
and Y represents the outcome information of all patients.
The first stage of sequential PS methods involves a model for the probability of A = 1
based on a predetermined function of observed covariates X. For the sake of illustration we
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consider a probit regression model with parameters γ which gives the following likelihood of
the PS model
l (γ|A, X) =

n 
Y

−1

Φ

(X0i γ)

Ai 
1−Ai
−1
0
1 − Φ (Xi γ)

(5.11)

i=1

where, Φ(·) is the normal CDF, i = 1, . . . , n denote indices of n patients and {Yi , Xi , Ai }
denote information on ith patient with Xi = (Xi1 , . . . , Xip )0 .
For the OS part, propensity score plays a key role by embedding treatment-covariate
relationship information into the outcome model. Keeping that in mind, we assume the
following normal regression model for the outcome stage where a function of the PS, say
e(X, γ) is included as a covariate along with the treatment variable A which is included to
estimate treatment causal effect.

Y |A, X, γ, ξ, δ = ξ0 + ξ1 e(X, γ) + δA + 

(5.12)

where, ξ1 controls the adjustment of PS in the outcome model, δ is the treatment effect and
 is the random error assumed to follow N (0, 1). The functional form of e(X, γ) determines
how PS is adjusted in the outcome model. For example, if we specify e(X, γ) = X 0 γ the
PS would be linearly adjusted in the outcome model (McCandless et al., 2009). Other than
directly including PS into the outcome model, we can also specify a membership such as
by its quantiles as discussed in Rosenbaum and Rubin (1983) in the context of matching
methods. The OS model corresponds to the following likelihood function

l (ξ, δ, γ|Y, A, X) ∝ exp

− 0.5

n
X

2

(Yi − ξ0 − ξ1 e(Xi , γ) − δAi )


(5.13)

i=1

In the traditional sequential PS methods, the estimation of δ is carried out in two separate
stages. The estimates of γ, say γ̂ are obtained from the PS likelihood (5.11) which is then
plugged in the OS likelihood function (5.13) and δ is estimated from l (ξ, δ, γ̂|Y, A, X).
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Unlike the sequential approach of the frequentist method, the Bayesian counterpart follows from the joint likelihood of the parameters ξ, δ, γ combining both PS (5.11) and OS
model (5.13) likelihood functions.

l (ξ, δ, γ|Y, A, X) ∝

n 
Y

−1

Φ

Ai 

(X0i γ)

1−Φ

−1

1−Ai

(X0i γ)

(5.14)

i=1


× exp

2



− 0.5 (Yi − ξ0 − ξ1 e(Xi , γ) − δAi )

(5.15)

Note that, in this joint formulation the PS parameter γ is considered stochastic along with
other parameters and by inclusion of the PS function e(X, γ) in the outcome model the
uncertainty in PS gets channelized to the estimation of δ. However, under this setting, the
posterior inference of γ involves both PS and OS model parameters leading the situation of
model feedback. Under a similar framework, Zigler et al. (2013) provided a mathematical
reasoning of this phenomenon following a latent variable formulation of probit link regression proposed by Albert and Chib (1993). According to their proposal, sampling the binary
response A from the PS likelihood (5.11) is equivalent to drawing a latent truncated normal
variable A? with mean X 0 γ and variance 1. With this notion, assuming a flat prior distribution on the real line for all parameters, the posterior distribution of the model parameters
in (5.14) and (5.15) is given by


p (ξ, δ, γ|Y, A, A? , X) ∝ exp −0.5{(A? − Xγ)0 (A? − Xγ) + Y? 0 Y? }

where, Y? = (Y − ξ0 1n − ξ1 e(X, γ) − δA), 1n is the n dimensional vector with all entries 1.
From the above joint formulation, the full conditional distribution of γ is given by



0
0
2
0 0
?
p (γ|·) ∝ exp −0.5 γ X X 1 + ξ1 γ − 2γ X {A + ξ1 (Y − ξ0 1n − δA)} .
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which corresponds to the kernel of a multivariate Normal distribution with mean
{X0 X (1 + ξ12 )}−1 [X0 {A? + ξ1 (Y − ξ0 1n − δA)}] and variance covariance matrix {X0 X (1 + ξ12 )}−1 .
We can clearly see that the mean part is dependent on the outcome model and if ξ1 6= 0, the
outcome information will influence the posterior update of γ thus causing model feedback.
Zigler et al. (2013) provided a more detailed account of the effect of model feedback.
Assuming e(X, γ) = X 0 γ, the OS mean part of the joint likelihood function (5.15) can be
expressed as a re-parameterization of the response surface model

ξ0 + ξ1 e(X, γ) + δA = (ξ0 + ξ1 γ0 ) + ξ1 γ1 X1 + ξ2 γ2 X2 + · · · + ξp γp Xp + δA

(5.16)

This re-parameterization illustrates the fact that in this formulation the outcome model
fails to reflect the association between the outcome and the individual covariates on the
response surface, rather it conditions on an one dimensional summary of the covariates in
the form of PS. Because of this dimension reduction, the OS stage parameters of the true
data generating model cannot be fully identified by the analysis model. To elaborate on this
fact, Zigler et al. (2013) considered the following true models on the treatment-covariate and
outcome-covariate surfaces

PS: Φ−1 {P (A = 1|X, γ)} = γ0 + γ1 X1 + · · · + γp Xp

(5.17)

OS: Y |X, A, α, δ = α0 + α1 X1 + · · · + αp Xp + δA + 

(5.18)

where, αk reflects true association between outcome and k th covariate. Note that, the joint
likelihood functions (5.14)-(5.15) can only recover the true treatment-covariate surface in
(5.17), but fail to estimate individual covariate-outcome association in (5.18) as it only
adjusts for the PS. Combining the above data generating model for the OS part with (5.16)
we get α0 = ξ0 + ξ1 γ0 , α1 = ξ1 γ1 , · · · , αp = ξp γp . Thus the analysis outcome model
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would correspond to the OS part of the data generating model only if αk = ξ1 γk for k 6= 0.
As Zigler et al. (2013) pointed out, if this relationship does not hold true then feedback
from the outcome model would affect the posterior estimation of γ in such a way that the
true association between treatment and covariates (5.17) cannot be recovered leading to
the violation of balancing score property of PS. On the other hand, in frequentist approach
this issue does not arise as the outcome model parameters do not update the PS model
parameters reflecting the true assignment mechanism to ensure balancing score property.

5.4.3

Model Feedback in PSBayes

Here we concentrate on the model feedback property in the context of original PSBayes
specification. Similar to the previous example, we are assuming two models - one at the
PS stage and another for the outcome stage. In the PS model we include all covariates
so that we can recover the entire covariate-treatment surface through the propensity score.
However, for the sake of illustration, we assume the following probit model in the PS model
specification

Φ−1 (P (A = 1|X, γ)) = X0 γ
which corresponds to the same PS likelihood model as in (5.11). Following Albert and
Chib (1993), the same likelihood corresponds to the specification of a latent vector A? with
mean vector Xγ and variance covariance matrix In which leads to the following likelihood
model


p (γ|A, A? , X) ∝ exp −0.5{(A? − Xγ)0 (A? − Xγ)}

(5.19)
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For the OS model, we consider a robust specification of the mean part by including the
spline function of the logit of the propensity score. In this process, both PS and OS models
share PS parameters causing an update of PS values in posterior calculation which results in
model feedback. For the sake of mathematical illustration, we focus on the spline function
in the mean function of the OS model (5.5) and ignore the parametric part g(·). Hence, the
OS model is specified as

a

Y |X; γ, αa =

q
X

j

α1ja ea (X, γ) +

j=0

K
X

α2ka (ea (X, γ) − tka )q+ + 

k=1

which corresponds to the following formulation of the OS model incorporating all patients’
information
Ya |X; γ, αa = C1 (γ)α1a + C2 (γ)α2a + 
. where,





C1 (γ) = 





1
1
..
.

ea (X1 , γ)
ea (X2 , γ)
..
.

e2a (X1 , γ)

···

e2a (X2 , γ) · · ·
..
..
.
.

1 ea (Xna , γ) e2a (Xn , γ) · · ·
t1 )q+

···
 (ea (X1 , γ) −

 (ea (X2 , γ) − t1a )q · · ·
+

C2 (γ) = 
..
..

.
.


(ea (Xn , γ) − t1a )q+ · · ·

eqa (X1 , γ)





eqa (X2 , γ) 

,
..

.


q
ea (Xn , γ)

(ea (X1 , γ) −

tKa )q+

(ea (X2 , γ) −
..
.

tKa )q+

(ea (Xn , γ) − tKa )q+






,





α2a ∼ NK 0, σα2 2 IK and  ∼ Nn (0, σy2 In ).
The above specification gives the potential outcome distribution under treatment a as

Ya |X; γ, αa ∼ Nn (C1 (γ)α1a , Σy (γ))
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where, Σy (γ) = σα2 2 C2 (γ)C2 (γ)0 + σy2 In . The OS likelihood is given by


a
p (γ, αa |Ya , X, A) ∝ exp −0.5{(Ya − C1 (γ))0 Σ−1
y (γ) (Y − C1 (γ))}

(5.20)

Combining the PS and OS likelihoods (5.19) and (5.20) the full conditional distribution of
PS parameters γ is given by

p(γ|·) ∝ exp [−0.5 {(γ 0 X0 Xγ − 2γ 0 X0 A? )
a
+ (Ya − C1 (γ))0 Σ−1
y (γ) (Y − C1 (γ))

(5.21)


(5.22)

Clearly, we see that although (5.21) only involves treatment and covariates, (5.22) involves
quantities from outcome and PS model parameters which implies that the full posterior distribution of γ depends on the response surface model quantities in the posterior calculation.
Hence, the propensity score is also updated by this process causing model feedback.
In a similar framework An and Little (2008) avoided this situation by approximating the

posterior distribution of γ by Np γ̂, I (γ̂)−1 where γ̂ is the maximum likelihood estimator of
γ in (5.19) and I (γ̂) is the observed Fisher information matrix. Due to this approximation,
the PS parameters γ are not impacted by the outcome model quantities as they are not drawn
from their exact posterior distributions and hence can avoid model feedback. However,
by treating the estimated PS parameters as a known quantity in the outcome stage, this
approach faces same limitations as the frequentist counterpart in misstating the uncertainty
in causal estimates.
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5.4.4

Augmentation

As noted by Zigler et al. (2013), the identifiability issue due to the implied parameterization in Bayesian PS formulation as discussed in the example we considered before is
not because of model feedback, but rather due to the dimension reduction from the entire
covariate-treatment surface to one dimensional summary of covariates in the form of PS.
Because of the constrained parameterization, the Bayesian approach fails to recover the entire covariate-outcome response surface. Instead of considering the OS model (5.12) with
a function of PS values only, Zigler et al. (2013) suggested an augmentation of individual
covariates in the outcome model (5.12) and the final model can be expressed as

Y |A, X, γ, ξ, δ, β = ξ0 + ξ1 e(X, γ) + δA + g(X + , β) + 

(5.23)

where, g(X + , β) is a function of individual covariates except at least one covariate which
is/are excluded from X in order to avoid multicollinearity and the corresponding parameters. Specifically, if we assume g(X + , β) = X + β where X + = (X2 , X3 , . . . , Xp )0 and
β = (β1 , . . . , βp−1 )0 , then the RHS of (5.16) yields

(ξ0 + ξ1 γ0 ) + ξ1 γ1 X1 + (ξ2 γ2 + β1 )X2 + · · · + (ξp γp + βp−1 )Xp + δA

(5.24)

which by comparing with the data generating outcome model (5.18) implies α1 = ξ1 γ1 and
for k ≥ 2, αk = ξk γk + βk−1 . By including the individual covariates in the response surface
this model ensures identifiability of the data generation model parameters at the outcome
stage.
The PSPP framework (Little and An, 2004; Zhang and Little, 2009) also builds the
methodology on the same notion of augmentation and includes a parametric function of
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individual covariates in the outcome model. They further showed that the PSPP method
possesses key double robustness property in the sense that the exact specification of the
augmentation function g(·) can be misstated without biasing estimates of marginal parameters of interest as long as the relationship between Y and e(X, γ) is modeled correctly. In
the proposed method we follow the same direction and include a similar g(X2 , . . . , Xp , β)
function in the OS model in addition to e(X, γ) which results in the specification of the final
OS model (5.5).

CHAPTER 6
SIMULATION STUDY

6.1

Overview

We conduct extensive simulation studies to evaluate and compare the performance of
BayesG and PSBayes methods in predicting the “best” treatment for a new patient across
a wide range of scenarios. The simulation setups are inspired by the scenario 1 from Zhang
et al. (2012b) although the metrics we consider are different from theirs. The simulation
dataset consists of 500 subjects having a binary treatment A, continuous covariates X and
a continuous outcome Y reflecting the causal diagram 3.1 in the sense that the treatment of
each subject is generated following a PS model solely based on the covariates and the outcome
is generated following a OS model based on both the treatments and the covariates. As the
covariates are present in both PS and OS data generating models they can be specified as
confounders as well. To effectively evaluate the optimal treatment prediction performance,
we consider five simulation scenarios where we consider linear and nonlinear mean functions
with single to multi modes in the outcome model mimicking wide range of real life situations.
The treatments are generated by the same PS model across all scenarios. To inspect and
validate the performance, we generate 100 synthetic datasets following the data generation
models and randomly partition each dataset allocating 80% of the observations to the training
data and 20% to the test data. We fit the models on the training data comprising of 400
observations and the optimal treatments are predicted based on the covariate information of
the subjects in the test data consisting of 100 observations. The predicted optimal treatments
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are matched with the true optimal treatments of the test data and prediction accuracy
measures are calculated.

6.2

Method Specification

We compare our proposed methods based on Bayesian g-formula approach (BayesG)
and PSPP Bayesian approach (PSBayes) with two versions of inverse probability weighting
(IPWE) and augmented inverse probability weighting methods (AIPWE) (Zhang et al.,
2012b), one corresponding to the correct specifications of PS and OS models, while in the
other one, the models are misspecified.

6.2.1

Proposed Methods

In the BayesG method, we consider the true causal model to be E [Y a |V; α] = α0 +α1 A+
α2 V +α12 AV and we estimate α = (α0 , α1 , α2 , α12 )0 in order to predict the optimal treatment.
The hyper-parameters of the prior distributions are specified following the prior distribution
suggestions in Roy et al. (2016). Specifically, we chose the variance covariance matrix of the
prior distributions of MSM parameters α to be Σπα = 103 I4 . The same specification is used
for the variance covariance matrix of the GP mean regression function parameters β while
its mean vector is assumed to be 0. For the Gibbs sampler, we specify the initial values as
α = 1, β = 1, σy2 = 1, η = 0.5, ρ = 50. For this approach, we directly draw from the full
posterior distributions of the parameters. We use 25,000 draws for the burn-in period and
an additional 25,000 draws in the iteration period provide sufficiently small MC error in all
scenarios.
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For the PSBayes approach, we consider a p-spline model of order 3 in the mean function
of the outcome model as this specification is sufficient for desired robustness in most cases.
The prior distribution hyper-parameters are determined following the prior specification of
our method. Because of the significantly higher number of parameters and complex model
specifications, we choose 100,000 number of draws for the burn-in and the same number
of draws for posterior computation. The whole MCMC procedure is performed using rjags
package in R which only requires the model specifications of the stochastic nodes along
with the specifications of the fixed nodes and initial values of the parameters. We treat
missing potential outcomes as parameters and we update them by repetitive draws from
their posterior predictive distribution. In this way, we account for the uncertainty in missing
data prediction.

6.2.2

Comparator Methods

We want to examine the performance of our methods compared to other methods proposed in the literature of optimal regime selection. Specifically, we considered two comparator methods - inverse probability treatment weighting (IPWE) and the doubly robust augmented inverse probability treatment weighting (AIPWE) (Zhang et al., 2012a), which are
described in section 2.2. The IPWE method requires one to correctly specify the propensity
score model while for AIPWE we need to additionally specify the outcome surface model.
However, due to the double robustness property, AIPWE method needs only one correct
specification. It is unlikely to correctly specify the regression models in real life situation.
Keeping this in mind, we consider two variants of IPWE and AIPWE specifications as our
comparator methods viz. IPWE-True, IPWE-Mis, AIPWE-True and AIPWE-Mis. Among
them, the true versions are based on the true data generating models. More specifically, in
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IPWE-True method the analysis PS model has same specification as the data generating PS
model, whereas the IPWE-Mis method has misspecified PS model. Similarly, for AIPWETrue method, both PS and OS models are correctly specified, but for AIPWE-Mis method,
both of the models are misspecified. The specifications of all the comparator methods are
inspired from Zhang et al. (2012b) simulation 1.
Irrespective of the simulation scenarios, the outcome regression models specify a class of
treatment regimes based on the observed covariates Gη = I(X0 η > 0), so that the optimal
treatment A? ∈ Gη . Both IPWE and AIPWE provide estimation of the average potential
outcome indexed by η and maximize these estimators in order to estimate η and thus define
the optimal treatment selection rule. However, both IPWE and AIPWE estimators are
non-smooth functions of η and hence the traditional optimization routines may fail. As an
alternative, following Zhang et al. (2012b) we used a genetic algorithm which is implemented
in the rgenoud package in R. We used the default argument values except we took max =T,
optim.method =Neider-Mead and pop.size=3000 as suggested in the documentation of the
package and also in the Zhang et al. (2012b). We took the starting.values=c(0,0,. . . ,0) and
set (−2, −2, . . . , −2)0 and (2, 2, . . . , 2)0 as lower and upper bounds of η.

6.3

Performance Comparison

6.3.1

Validation

The primary objective of this simulation study is to evaluate how well the methods can
predict the treatment assignment for a new patient. Evaluation of prediction performance
requires the consideration of two separate datasets - one for model building and estimation
(training) and another for prediction and validation (test). One way to carry out such
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validation technique is to follow hold-out strategy where the whole dataset is randomly
divided into two parts for training and testing. The model is fit using the training set and
the optimal treatments are predicted for the test data using the test data confounders. The
predicted treatment assignments are matched with the observed treatment assignments in
the test data which gives a summary of the prediction accuracy. Finally, this whole process
is repeated multiple times to give an aggregated prediction accuracy measurement. Due to
heavy computational cost, we parallelized the whole process into 100 array jobs which was
run in 10 parallel nodes of Gaea, a high performance 60 node CPU/GPU hybrid cluster at
Northern Illinois Universitys Center for Research Computing and Data. Each process was
assigned computation for 1 holdout data. For BayesG approach, each holdout computation
took 5 hours on average for 50,000 iterations while the PSBayes approach took 1 hour on
average with 200,000 iterations.

6.3.2

Prediction Measure

For each holdout sample, we can obtain a 2 × 2 confusion matrix by matching the predicted optimal treatments with the true optimal treatments from the simulation settings
which would provide us with the sensitivity, specificity and prediction accuracy. Let Z be a
dichotomous variable which can take values 0 or 1. Let Z ? be the true value of Z and Ẑ be
the predicted value of Z. Then in the classification setting, the sensitivity and specificity are
given by P (Ẑ = 1|Z ? = 1) and P (Ẑ = 0|Z ? = 0) respectively and the prediction accuracy
gives the overall strength of matching and is defined as P (Ẑ = Z ? ).
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In our case, let A?ik be the true optimal treatment choice for ith patient in k th holdout
test data and let Âik be the corresponding predicted optimal treatment. Then the sensitivity
and specificity for k th holdout test data can be estimated as


Pntest 
Pntest 
?
?
I
=
0
I
=
1
Â
=
A
Â
=
A
ik
ik
ik
ik
i=1
i=1
Pntest
Pntest
, speck =
sensk =
?
?
i=1 I (Aik = 1)
i=1 I (Aik = 0)
where, ntest is the number of patients in the test data. The prediction accuracy is estimated
by matching the predicted treatment with the observed

acck =

6.4

ntest 

1 X
?
I Aik = Âik

ntest

i=1

Simulation 1

In this simulation, we follow the simulation 1 setting of Zhang et al. (2012b) to generate
500 observations (Yi , Ai , Xi ), i = 1(1)500 where, Xi = (Xi1 , Xi2 )0 . Xi1 and Xi2 are independently generated from U (−1.5, 1.5). Ai is generated from a Bernoulli distribution with
success probability π(Xi ) where the following logit model is used to generate π(Xi ) given
the values of Xi
logit{π(X)} = −1 + 0.8X12 + 0.8X22
and Yi is generated using the following outcome model given Ai and Xi

(Y |A, X) = µ(A, X) + 
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Table 6.1:
Accuracy
Model
Mean Median
BayesG
0.768
0.78
PSBayes
0.85
0.925
IPWE-True 0.876
0.91
IPWE-Mis
0.674
0.61
AIPWE-True 0.914
0.92
AIPWE-Mis 0.525
0.54

Simulation 1 prediction measures.
Sensitivity
Specificity
SD Mean Median SD Mean Median SD
0.099 0.999
1
0.005 0.511
0.536 0.209
0.136 0.954
0.979 0.053 0.732
0.903 0.288
0.11 0.887
0.918 0.125 0.863
0.923 0.188
0.138 0.906
0.912 0.054 0.417
0.302 0.283
0.048 0.917
0.931 0.085 0.911
0.953 0.106
0.044
1
1
0
0
0
0

where, the mean function µ(A, X) = 2 − 1.5X12 − 1.5X22 + 3X1 X2 + A(−0.1 − X1 + X2) and
the error  ∼ N (0, 1). From the outcome model, the true optimal treatment of ith patient
can be deduced as
A?i = I(Xi1 − Xi2 < −0.1)
To estimate the optimal regime, we assume the same specification for the proposed
methods as discussed before. For the comparator methods, we assume a correct and an
incorrect specification of PS and OS models. In particular, for the correctly specified PS
model we posit logit{πt (X; γ)} = γ0 + γ1 X12 + γ2 X22 which belong to the same class of the
data generating PS model and for the misspecified version of the PS model, we assume
logit{πm (X; γ)} = γ0 + γ1 X1 + γ2 X2 . As for the outcome regression model, we consider
µt (A, X, β) = β0 + β1 X12 + β2 X22 + β3 X1 X2 + A(β4 + β5 X1 + β6 X2 ) corresponding to the
correct specification and µm (A, X, β) = β0 + β1 X1 + β2 X2 + A(β3 + β4 X1 + β5 X2 ) for the
misspecified model. Both PS and OS model parameters are estimated by standard GLM
procedure.
Table 6.1 shows the comparison of accuracy, sensitivity and specificity measures among
all methods we discussed here. The mean, median and standard deviation of each prediction
measure over 100 holdout samples are displayed. The empirical distribution of the predic-
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tion measurements may not be symmetric and hence we consider median as the centrality
measure.
As we see from the result, the BayesG approach predict the true optimal treatments
76.8% of the times on average. Interestingly, the median sensitivity is 1 i.e. this approach
correctly predicts all true treatment choices that are 1. However, the median specificity is
only 53.6% resulting moderate overall accuracy performance. On the other hand, we see
that PSBayes approach performs substantially well in this setting as it correctly predicts
true treatment 1 almost 98% and true treatment 0 90% of the times. Overall this approach
correctly predicts the treatments 92.5% on average. Among the inverse probability methods
the true variants of AIPWE and IPWE perform considerably as both models are correctly
specified, however, both of them have marginally lower accuracy measure than PSBayes on
average. But in real life situations, we rarely anticipate the true data generating models
and correctly specify them as the analysis models. Therefore, the misspecified models would
give us a glimpse of real life scenarios. Here, also we see that while the true specifications of
IP based methods perform comparably, their misspecified counterparts perform poorly. For
instance, while IPWE with correct PS model could predict the true optimal treatment around
90% of the times, the misspecified version could only show 61% prediction accuracy. Under
misspecified models, IPWE methods show better performance than AIPWE as in IPWE
only the PS model is misspecified, but in AIPWE both PS and OS models are misspecified.
Taken together, these key findings lead into the conclusion that incorrectly specified models
heavily affect the prediction performance and the extent of under performance depends on
the extent of misspecification.
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Table 6.2:
Accuracy
Model
Mean Median
BayesG
0.756
0.77
PSBayes
0.733
0.76
IPWE-True 0.923
0.93
IPWE-Mis
0.82
0.84
AIPWE-True 0.959
0.96
AIPWE-Mis 0.889
0.94

Simulation 2 prediction measures.
Sensitivity
Specificity
SD Mean Median SD Mean Median SD
0.125 0.943
1
0.099 0.549
0.636 0.293
0.137 0.825
0.854 0.138 0.624
0.8
0.348
0.046 0.918
0.926 0.075 0.927
0.955 0.088
0.122 0.943
0.96
0.049 0.681
0.713 0.246
0.027 0.959
0.978 0.046 0.957
0.978 0.055
0.139 0.949
0.963 0.053 0.822
0.924 0.276

6.5

Simulation 2

Data Generation. This setting is similar to the simulation 1 except the mean function
of the outcome data generation model is not an additive model. Similar to Simulation 1, we
independently generate the covariates Xi1 and Xi2 from U (−1.5, 1.5) and Ai from the logit
PS model
logit{P (A = 1)|X} = −1 + 0.8X12 + 0.8X22
. Yi is generated using the following outcome model given Ai and Xi

(Y |A, X) = µ(A, X) + 

where, the mean function µ(A, X) = exp (2 − 1.5X12 − 1.5X22 + 3X1 X2 + A(−0.1 − X1 + X2 ))
and the error  ∼ N (0, 1). Here also, the true optimal treatment is defined as

A? = I(X1 − X2 < −0.1)

Result. The simulation 2 results are displayed in table 6.2. Note that, in this setting, we
purposely did not include an additive mean function in the outcome data generating model
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to check the performance of the comparator methods in such scenarios. In summary, both
correct and incorrect specifications of IPWE and AIPWE display better performance than
our proposed approaches probably due to the fact that the model space of the proposed
outcome models does not include non-linear models.
In particular, both BayesG and PSBayes methods correctly predict the true optimal
treatments around 77% of the times, whereas the true variants of IPWE and AIPWE are
93% and 96% accurate. AIPWE-Mis achieves 94% overall accuracy, which approximates the
true version, while IPWE with an incorrect PS model is 84% accurate. Among our methods,
PSBayes perform marginally better than BayesG and predicts the true optimal treatment
77% of the times. The other measures such as sensitivity and specificity follows the same
pattern.

6.6

Simulation 3

Data Generation. In this setting, we consider three confounders X = (X1 , X2 , X3 )0
and generate Xi , i = 1(1)500 as follows.






 



0
0 
 X1 
 0   0.25



  
 X  ∼ N  0  ,  0

0.25
0.175
 2 

  



  
0
0 0.175 0.25
X3
All three covariates contribute to generate treatments using the following model

logit(P (X)) = −1 + 0.8X12 + 0.8X22 + 0.8X32
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Table 6.3: Simulation 3 prediction measures
Model
BayesG
PSBayes
IPWE (True)
IPWE (Mis)
AIPWE(True)
AIPWE (Mis)

Mean
0.917
0.887
0.811
0.797
0.872
0.84

Accuracy
Median
0.93
0.9
0.815
0.815
0.88
0.86

SD
0.056
0.068
0.102
0.091
0.078
0.089

Sensitivity
Mean Median
0.943
0.965
0.891
0.931
0.887
0.925
0.95
0.981
0.907
0.958
0.888
0.925

SD Mean
0.076 0.883
0.1
0.881
0.122 0.711
0.072 0.594
0.11 0.825
0.116 0.775

Specificity
Median
0.92
0.919
0.796
0.629
0.873
0.814

SD
0.125
0.122
0.257
0.216
0.182
0.196

Based on the treatment Ai and covariates Xi , the outcomes Yi are simulated as

(Y |A, X) ∼ N (µ(A, X), 1)

where, µ(A, X) = exp(2 − 1.5X32 + 3X1 X3 + A(−0.1 − X1 + X2 )). Note that, X3 is included
in the mean function but not included in the interaction term with treatment and can be
considered as non-effect modifier W as in the causal inference literature. As the interaction
term does not change the optimal treatment is defined by the same decision rule as in
simulation 1 and simulation 2.
Result. From the simulation result in Table 6.3, we see that the BayesG method outperforms all other methods in terms of higher sensitivity, specificity and overall accuracy
in the prediction of true optimal treatments. The reason behind this finding directs to
the presence of the non-effect modifier X3 in the data generating model. The PSBayes has
shown marginally inferior prediction profiles. Among the IP methods, AIPWE show a better
prediction measures than IPWE.
Specifically, we see that BayesG is around 93% accurate in predicting the true best
treatment. PSBayes also performs comparably and shows 90% accuracy. Among the comparator methods, AIPWE performs closely since the true specification is 88% accurate and
the misspecification is 86% accurate. The IPWE only relies on PS models and does not have
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enough power to detect true signals and performs suboptimally by predicting the true treatment around 80% of the times. If we consider other measures, all methods except PSBayes
have higher sensitivity than specificity which means most of the methods correctly predict
treatment 1 most of the times, while it is not true for treatment 0. PSBayes has similar
sensitivity and specificity profile which might be due to the fact that it fits the outcome
model for both treatment groups separately.

6.7

Simulation 4

Data Generation. In this simulation setting we consider a bimodal mean function. Here
we simulate the covariates X and the treatment A in the similar fashion as in Simulation 1
or 2. Additionally, we simulate a binary variable Bi , i = 1(1)500 from B ∼ Bernoulli(0.5)
as a cluster indicator. Next based on the treatments, the covariates and cluster membership
variable we simulate the outcomes as

(Y |A, X) ∼ N (µ(A, X), 1)

where, µ(A, X) = 2 − 1.5X12 − 1.5X22 + 3X1 X2 + A(−0.1 − X1 + X2 ) + 10(B − B̄).
Here, also the optimal treatment would be decided by the same decision rule as in the
other simulation settings as the interaction term is same across all settings.
Result. In this setting, the outcome distribution is not unimodal and somewhat reflects
a non-ideal scenario. Here as we see from the table 6.4, the DDP specification of the PSBayes
method outperforms all other methods in having higher prediction accuracy, sensitivity and
specificity by a substantial margin. The PSBayes method has overall 94% accuracy while
BayesG and the IP methods with true specifications are less than 80% accurate in prediction
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Table 6.4: Simulation 4 prediction measures.
Accuracy
Sensitivity
Specificity
Model
Mean Median SD Mean Median SD Mean Median SD
BayesG
0.742
0.77
0.133 0.952
1
0.101 0.494
0.526 0.286
PSBayes-DDP 0.838
0.94
0.183
0.9
0.981 0.184 0.763
0.932 0.345
IPWE-True
0.708
0.73
0.177 0.696
0.734
0.26 0.723
0.786 0.279
IPWE-Mis
0.673
0.65
0.154 0.836
0.904 0.173 0.482
0.415
0.31
AIPWE-True 0.768
0.78
0.144 0.768
0.863 0.237 0.763
0.833 0.241
AIPWE-Mis 0.665
0.63
0.153 0.854
0.9
0.14 0.442
0.372 0.295
of the true best treatment option for the new patients. The misspecified versions of the IP
method perform poorly as they only show around 65% accuracy. The BayesG method has a
very high sensitivity and predicts the true treatment 1 almost all the times, but has a lower
accuracy due to having only 52.6% specificity. Here also, we see a clear disparity between
the sensitivity and specificity measures for all methods except PSBayes.

6.8

Simulation 5

Data Generation. Here we consider a skewed outcome distribution. To do that, we
simulate the covariates X and the treatment A in the similar fashion as in Simulation 1,
2 or 4. For the outcome generation, we follow (Y |A, X) = µ(A, X) +  where, we assume
µ(A, X) = 2 − 1.5X12 − 1.5X22 + 3X1 X2 + A(−0.1 − X1 + X2 ) and  is generated from
a skewed mixture distribution. Specifically, we consider a mixture setup to generate  as
|? ∼ N (? , 3) with ? ∼ LogNormal(2, 1).
Here also the optimal treatment would be decided by the same decision rule as in the
other simulation settings as the interaction term is same across all settings.
Result. This situation reflects a skewed outcome case which occurs frequently in real life
scenarios. Here also we see, the DDP specification of the PSBayes method outperforms all
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Table 6.5: Simulation 5 prediction measures
Model
BayesG
PSBayes-DDP
IPWE (True)
IPWE (Mis)
AIPWE(True)
AIPWE (Mis)

Mean
0.622
0.749
0.572
0.609
0.59
0.595

Accuracy
Median
0.595
0.8
0.6
0.64
0.625
0.585

SD
0.191
0.164
0.225
0.164
0.224
0.205

Sensitivity
Mean Median
0.744
0.838
0.79
0.945
0.57
0.604
0.832
0.869
0.597
0.673
0.682
0.733

SD Mean
0.283 0.483
0.254 0.708
0.302 0.576
0.159 0.353
0.294 0.59
0.262 0.497

Specificity
Median
0.517
0.814
0.629
0.367
0.62
0.392

SD
0.352
0.314
0.332
0.232
0.342
0.335

other methods in having higher prediction accuracy, sensitivity and specificity by a significant
margin. Only the PSBayes method has more than 80% overall accuracy. Close to 95% of
the times, it predicted correct true treatment 1 cases, whereas for true treatment 0 cases the
accuracy is around 82%. In contrast, all other methods show overall accuracy around 60%.
The sensitivity of BayesG, misspecified IP models are significantly higher than the specificity,
while the true versions have similar sensitivity and specificity profiles. Interestingly, the
incorrect specification of the IP methods sometimes outperform the true version of these
methods highlighting the fact that the performance difference is more clear when the outcome
distribution is symmetric. But in presence of skewed distribution, the difference is more
nuanced.

CHAPTER 7
DISCUSSION

In this dissertation, we propose two Bayesian semi-parametric methods; BayesG and
PSBayes to estimate the optimal treatment decision for a new patient based on his/her
biological profile in a binary treatment setting. Our methods are based on an observational
study where we have access to the information of a group of patients about their biological
profile, assigned treatments and their response to the treatments. The BayesG method
builds on the notion of Bayesian parametric g-formula and extends it to specify GP prior
within a marginal structural model framework which allows for nonparametric estimation of
the mean function. Advantage of using this method includes higher efficiency in estimation
of the causal parameters due to adherence to the likelihood based parametric g-formula
and incorporating prior information through Bayesian setting to reduce variability in the
estimation. However, one limitation of the BayesG approach is that the treatment decision
is driven by the marginal structural model which only involves the effect modifier among
the confounders. Hence, one should be very cautious in identifying the true effect modifiers
and in specifying a correct MSM such that it belongs to the class of true MSMs. In the
simulation studies, the MSMs of the analysis model are specified based on the outcome model.
Observing the close analogy between treatment assignment and missing data mechanisms
our second approach is developed on the PSPP framework from the missing data literature.
We train our model with the information of the observed group of patients and impute
missing potential outcomes of the new patient under each treatment group. We then compare
the empirical distributions of the treatment groups and estimate the optimal treatment
employing a stochastic ordering approach.
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Finally, we consider five different simulation scenarios reflecting wide range of situations where we compare the prediction performance of our methods with comparator semiparametric estimation approaches such as inverse probability weighting (IPWE) and the
double robust augmented inverse probability weighting (AIPWE). In the presence of additive mean functions, we found that our methods show better performance than the IP based
methods and vice-versa. Specifically, in the presence of non effect modifier W , the BayesG
method performs better than all other method, whereas in other additive mean function
scenarios PSBayes shows higher median accuracy in predicting true optimal treatments.
Furthermore, the BNP specification of PSBayes method outperform other methods in the
last two scenarios, where the outcomes are generated from a multimodal or a positively
skewed distribution.
Throughout this dissertation, we discussed the methods and literature related to timefixed setting. However, as we discussed in chapter 2, in lot of practical applications involving
chronic diseases the data often originate from a longitudinal setting raising a natural question
- how to determine the “best” treatment decision at a certain stage of the multistage therapy
aka dynamic treatment regime (DTR) based on the accrued information on a patient. We
seek to answer this question by extending our proposed method in presence of time varying
confounders and treatments as one of our future works.
For concreteness, let {Y (t), A(t), X(t)} be the outcome, treatment and confounder information of a patient collected at a discrete time t. In addition, let the history of exposure
upto and including time t be denoted as Ā(t) = {A(u) : 0 ≤ u ≤ t}. Similarly, the
time varying covariates and outcomes are denoted as X̄(t) = {X(u) : 0 ≤ u ≤ t} and
Ȳ (t) = {Y (u) : 0 ≤ u ≤ t}. Under the temporal assumption that at every time point X(t)
occurs before A(t) we can specify two models to facilitate Bayesian parametric g-formula
- (1) for the confounder at time t based on accrued information available upto time t − 1
i.e. p(X(t)|ā(t), x̄(t − 1), ȳ(t − 1), ā(t − 1)) and (2) for the outcome Y (t) at time t, based
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on the accrued information available on treatment and confounder history upto time t and
the outcome history upto time t − 1 i.e. p(Y (t)|ā(t), x̄(t), ȳ(t − 1)). Then similar to the
BayesG method, we can integrate the nuisance parameter and covariate to match with the
MSM specification. Several works have been done in this area in the context of MSM and
DTR (Robins, 1998a, 1999a, 2000; Robins et al., 2000; Hernán et al., 2000; Murphy et al.,
2001; Keil et al., 2015). Keil et al. (2015) considered a similar method for estimating the
causal parameters in the setting of Bayesian parametric g-formula. However, their method
relies on parametric assumption which we can relax by considering flexible non-parametric
likelihood model.
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